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Pluripotency is highly dynamic and progresses
through a continuum of pluripotent stem cell states.
The two states that bookend the pluripotency contin-
uum, naive and primed, are well characterized, but
our understanding of the intermediate states and
transitions between them remains incomplete. Here,
we dissect the dynamics of pluripotent state transi-
tions underlying pre- to post-implantation epiblast
differentiation. Through comprehensive mapping of
the proteome, phosphoproteome, transcriptome,
and epigenome of embryonic stem cells transitioning
from naive to primed pluripotency, we find that rapid,
acute, and widespread changes to the phosphopro-
teome precede ordered changes to the epigenome,
transcriptome, and proteome. Reconstruction of the
kinase-substrate networks reveals signaling cas-
cades, dynamics, and crosstalk. Distinct waves of
global proteomic changes mark discrete phases of
pluripotency, with cell-state-specific surfacemarkers
tracking pluripotent state transitions. Our data pro-
vide new insights into multi-layered control of the
phased progression of pluripotency and a foundation
for modeling mechanisms regulating pluripotent
state transitions (www.stemcellatlas.org).
INTRODUCTION
Pluripotency describes the developmental potential of a cell to
give rise to derivatives of all three primary germ layers.
Although pluripotency is ephemeral in vivo, pluripotent stem
cells (PSCs), derived from various stages of early embryonic
development, can self-renew indefinitely in vitro under defined
culture conditions while retaining their pluripotent status (Nich-
ols and Smith, 2009). Studies of the early mouse embryo andCell Systems 8, 427–445,
This is an open access article under the CC BY-NPSCs in culture have led to the proposition that embryonic plu-
ripotency is highly dynamic and proceeds through a contin-
uum of pluripotent stem cell states (De Los Angeles et al.,
2015; Hackett and Surani, 2014; Nichols and Smith, 2009;
Rossant and Tam, 2017; Shahbazi et al., 2017; Weinberger
et al., 2016; Wu and Izpisua Belmonte, 2015). At one end of
this continuum is the naive pluripotent state (Nichols and
Smith, 2009), sometimes also referred to as the ground state
(Hackett and Surani, 2014; Marks et al., 2012; Ying et al.,
2008), representing the most unrestricted developmental po-
tential that exists in the pre-implantation mouse embryo from
approximately embryonic day 3.75 (E3.75) to E4.75 (Boroviak
et al., 2014). At the other end of this continuum is the primed
pluripotent state, representing pluripotent cells from post-im-
plantation mouse epiblasts (E5.5–E8.25), which are lineage
primed for differentiation.
Embryonic stem cells (ESCs), derived from the inner cell mass
(ICM) of pre-implantation mouse blastocysts (Figure 1A) and
maintained under defined culture conditions known as 2i+LIF
(Ying et al., 2008), most closely resemble naive epiblasts of the
pre-implantation embryo (Boroviak et al., 2014, 2015). Hence,
ESCs are considered to capture the naive pluripotent state.
Epiblast stem cells (EpiSCs), isolated from pre-gastrulation
(E5.5) to late-bud (E8.25) stage post-implantation mouse epi-
blasts (Brons et al., 2007; Tesar et al., 2007) (Figure 1A), are
developmentally comparable to the late-gastrulation stage
(E7.0) embryo, irrespective of the original developmental stage
(E5.5–E8.25) of their source tissue (Kojima et al., 2014); these
cells are considered an archetypal representative of the primed
pluripotent state. Interestingly, conventional human ESCs
(hESCs), derived from pre-implantation human blastocysts,
exhibit molecular and morphological characteristics that are
more similar to primed EpiSCs than to naive ESCs (Davidson
et al., 2015; De Los Angeles et al., 2015; Hackett and Surani,
2014; Rossant and Tam, 2017; Weinberger et al., 2016; Wu
and Izpisua Belmonte, 2015). Several protocols that reprogram
hESCs back to the ground state have been proposed (Chan
et al., 2013; Gafni et al., 2013; Takashima et al., 2014; Theunis-
sen et al., 2014; Ware et al., 2014), but they each generateMay 22, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 427
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. High-Temporal-Resolution Profiling of the Proteome, Phosphoproteome, Transcriptome, and Epigenome during ESC to EpiLC
Transition
(A) Developmental events during embryogenesis in mouse embryos. ICM, inner cell mass; ESCs, embryonic stem cells; TE, trophectoderm; PE, primitive
endoderm; EpiLC, epiblast-like cells; EpiSCs, epiblast stem cells; PGCs, primordial stem cells.
(B) Schematic showing EpiLC induction from ESCs grown in 2i+LIF medium. Proteome, phosphoproteome, transcriptome, and epigenome were profiled at
indicated time points. Phase contrast images correspond to representative ESC colony grown in 2i+LIF medium (left) and cells undergoing morphological
changes at 72 h post EpiLC induction (right).
(C) Schematic of mass spectrometry (MS)-based experimental protocols used for proteome and phosphoproteome profiling.
(D) Summary statistics of proteins, phosphosites, transcripts, and epigenetic marks profiled.
See also Figures S1 and S2.‘‘naive’’ hESCs with distinct transcriptional profiles (Davidson
et al., 2015; Huang et al., 2014) and fail to recover the naive
epiblast methylation landscape (Pastor et al., 2016). Although
these purported naive hESCs satisfy some features of mouse
criteria for the naive pluripotent state, whether they can be
considered equivalent to naive mouse ESCs remains an open
question.428 Cell Systems 8, 427–445, May 22, 2019ESCs are highly competent to form high-contribution mouse
chimeras with germline transmission, following microinjection
intopre-implantationembryos.EpiSCs,however,donot integrate
well into host blastocysts, likely because they correspond to a
developmentally advanced stage compared to the host pre-im-
plantation environment and thus, contribute poorly or not at all
to blastocyst chimeras (Dejosez and Zwaka, 2012; Hackett and
Surani, 2014; Han et al., 2010; Nichols and Smith, 2009; Wein-
berger et al., 2016; Wu and Izpisua Belmonte, 2015). Conversely,
when grafted into post-implantation (E7.5) embryos inwhole-em-
bryo culture, EpiSCs but not ESCs efficiently incorporate into the
host and contribute to all three germ layers (Huang et al., 2012).
Consequently, primed EpiSCs are considered to be functionally
and developmentally distinct from naive epiblasts and ESCs (De
Los Angeles et al., 2015; Weinberger et al., 2016). While the naive
and primed states, which bookend the pluripotency continuum,
are well characterized (Kojima et al., 2014; Marks et al., 2012),
our understanding of the intermediate pluripotent states and the
transitions between them remains incomplete.
Cell signaling underlies transcriptional and/or epigenetic con-
trol of a vastmajority of cell fate decisions during early embryonic
development (Dejosez and Zwaka, 2012; Hackett and Surani,
2014; Rossant and Tam, 2017; Weinberger et al., 2016). Yet,
our understanding of the signaling dynamics during pluripotent
state transitions and how they instruct epigenetic and/or
transcriptional programs controlling ICM to post-implantation
epiblast differentiation remains poorly understood. Recent ad-
vances inmass-spectrometry (MS)-based proteomics now allow
for near-comprehensive characterization of proteomes (Aeber-
sold and Mann, 2016) and deep phosphoproteome coverage
(Needham et al., 2019). To elucidate the signaling and molecular
dynamics that underlie pluripotent state transitions, here we
generated comprehensive high-temporal-resolution maps of
the phosphoproteome, proteome, transcriptome, and epige-
nome of ESCs transitioning from naive to primed pluripotency.
Our data provide new insights into the multi-layered control of
the phased progression of pluripotency and a foundation for
investigating mechanisms underlying ICM to post-implantation
epiblast differentiation.
RESULTS
High-Temporal-Resolution Maps of the Proteome,
Phosphoproteome, Transcriptome, and Epigenome of
Cells Transitioning from Naive to Primed Pluripotency
To elucidate the temporal dynamics of the phosphoproteome,
proteome, epigenome, and transcriptome during the transition
from naive to primed pluripotency, we employed a previously
validated system to induce naive mouse ESCs to post-implanta-
tion pre-gastrulating epiblast-like cells (EpiLCs) (Buecker et al.,
2014; Hayashi et al., 2011; Kurimoto et al., 2015; Shirane et al.,
2016), which more closely resemble the early post-implantation
epiblast (E5.5–E6.5) compared to EpiSCs (Hayashi et al., 2011).
EpiLCswere induced by plating naive ESCs, grown in the ground
state under serum-free 2i+LIF medium, onto fibronectin-coated
plates in N2B27 medium containing activin A, bFGF, and
knockout serum replacement (KOSR, 1%) (Hayashi et al.,
2011). Consistent with previous reports, within 48 h of EpiLC in-
duction, morphological transformation in the form of flattened
epithelial structures resembling epiblasts was evident (Fig-
ure S1A). RNA analysis using quantitative RT-PCR confirmed
the downregulation of naive pluripotency- and/or ICM-associ-
ated genes (Nanog, Klf4, and Prdm14) accompanied by the in-
duction of post-implantation epiblast-associated genes (Fgf5,
Otx2, and Pou3f1/Oct6) (Figure S1B) (Buecker et al., 2014; Hay-
ashi et al., 2011; Kalkan et al., 2017). Although no dramaticchanges in transcript levels of these marker genes were evident
after 48 h post induction, we included the 72-h time point in our
analyses to capture changes to the proteome that may lag
changes to the transcriptome.
Using advances in MS-based proteomics (Kulak et al., 2014)
and our EasyPhos workflow (Humphrey et al., 2015, 2018),
together with next-generation sequencing, we generated maps
of the phosphoproteome, proteome, transcriptome, and epige-
nome of cells at various time points during the 72-h ESC to EpiLC
transition (Figure 1B; http://www.stemcellatlas.org). To capture
the earliest signaling responses, we profiled the phosphopro-
teome of transitioning cells at high temporal resolution within
the first hour post induction (Figure 1B). All MS experiments
were performed in biological quadruplicates. In addition, to
enhance coverage of the proteome measurements, we pooled
the four biological replicates from each time point and performed
StageTip-based strong cation exchange (SCX) fractionation (Ish-
ihama et al., 2006) of this pooled sample for the proteome runs
(Figures 1C, S2A, and S2B). All MS data were analyzed using
the MaxQuant computational platform (Cox and Mann, 2008;
Tyanova et al., 2016).
Our single-run EasyPhos workflow produced excellent phos-
phopeptide coverage, quantifying over 15,000 phosphopeptides
in every run (Figure S2C). This yielded a total of 30,726 distinct
phosphopeptides from which we identified 37,619 individual
phosphorylation sites (Figure 1D). Phosphosite localization
confidence was high, with >80% (26,180) of the quantified phos-
phosites accurately localized to a single amino acid (mean local-
ization probability for quantified sites: 0.96) (Figure S2D; STAR
Methods). A total of 17,866 phosphosites and over half of the
class 1 phosphosites (14,103) were quantified across all 12
time points analyzed (Figure 1D; Table S1). From our proteome
runs, we identified over 160,000 distinct peptides and quantified
a grand total of 10,597 proteins across all samples and 9,250
proteins in every sample (Figure 1D). Quantification coverage
at the proteome level was also very high, with 9,250 proteins
quantified across all profiled time points (Figure 1D; Table S2).
Using paired-end RNA sequencing (RNA-seq), we mapped the
transcriptome across 8 time points during the 72-h time course
and detected a total of 16,734 transcripts (reads per kilobase of
transcript, per million mapped reads [RPKM] > 1) corresponding
to 13,600 unique genes (Figures 1D and S2E; Table S3). Chro-
matin immunoprecipitation sequencing (ChIP-seq) analyses of
the chromatin, collected from the same 8 time points, using anti-
bodies against common histone modifications (H3K4me1,
H3K4me3, and H3K27ac: associated with the promoters of tran-
scriptionally active genes; H3K27me3 and H3K9me2: associated
with the promoters of silent genes) and RNA polymerase II
(RNAPII) identified several thousand transcriptionally active and/
or poised genes (Figures 1D and S2F; Table S4).
ESCs Exit the Naive Pluripotent State by About 36 h Post
Induction
Principal-component analysis (PCA) and unsupervised hierar-
chical clustering of the transcriptome, proteome, phosphopro-
teome, or epigenome revealed clear time-dependent separation
of the data (Figures 2A–2C and S3), with global changes to the
phosphoproteome evident as early as 5 min post induction
(Figure 2C), suggesting that the clustering is driven largely byCell Systems 8, 427–445, May 22, 2019 429
Figure 2. Temporal Dynamics of the Proteome, Phosphoproteome, and Transcriptome during ESC to EpiLC Transition
(A–C) Principal-component analysis (PCA) of the transcriptome (A), proteome (B), and phosphoproteome (C) during EpiLC induction. Each circle represents data
from a sample collected at a particular time point during ESC to EpiLC transition, with lighter and darker shades of purple denoting earlier and later time points,
respectively. Filled green squares represent transcriptomic data from Kalkan et al. (2017).
(D) Temporal dynamics of global changes in the proteome, phosphoproteome, transcriptome, and epigenome during ESC to EpiLC transition. Changes in the
phosphorylation level of a given phosphosite were normalized to the changes in corresponding protein level.
(E) Density plot showing the distribution of magnitude of changes at the protein, mRNA, and phosphosite level. Changes in phosphosite levels were normalized
as in (D).
(F) Fraction of phosphosites, mRNAs, and proteins dynamically regulated during EpiLC induction, as assessed using ANOVA test. Changes in phosphosite levels
were normalized as in (D).
(G) Venn diagram showing overlap among genes encoding differentially regulated mRNAs, proteins, and/or phosphosites during ESC to EpiLC transition. Only
genes with both protein and mRNA levels quantified were used for this analysis.
See also Figures S3 and S4.differences in the underlying biological signal across various time
points. PCA analysis of our transcriptomic data, in conjunction
with the recently published RNA-seq data obtained from ESCs
transitioning out of naive ground-state pluripotency (0 h, 16 h,
25 h-Rex1high, and 25 h-Rex1low) (Kalkan et al., 2017), revealed430 Cell Systems 8, 427–445, May 22, 2019temporal concordance of the datasets from the two studies (Fig-
ure 2A), suggesting that the biological signal driving these tem-
poral clusters is highly reproducible. The transcriptome at 24 h
post EpiLC induction clustered with those from 16-h- and
25-h-Rex1high cells (Figure 2A), with the latter previously shown
to be in a reversible phase preceding extinction of the naive state
(Kalkan et al., 2017). Consistent with 25-h-Rex1high cells, Rex1
(Zfp42) expression in cells at 24 h post EpiLC-induction re-
mained high at the mRNA and protein level (Tables S2 and S3).
In contrast, the transcriptome at the 36-h time point during
ESC to EpiLC transition clustered with that of the 25-h-Rex1low
cells, the primary products of exit from naive pluripotency
(Kalkan et al., 2017). Consistent with 25-h-Rex1low cells that
exited the naive ground state, Rex1 expression was downregu-
lated by10-fold at 36 h post EpiLC induction (Table S3). Collec-
tively, these data suggest that by about 36 h post induction, cells
had exited the naive pluripotent state.
Phosphoproteome Dynamics Precede Changes to the
Epigenome, Transcriptome, and Proteome
To understand the sequence ofmolecular events and the tempo-
ral kinetics that transform cellular identity, we next examined the
timing, scale, and magnitude of changes to the proteome, phos-
phoproteome, transcriptome, and epigenome as ESCs transition
through various phases of pluripotency. Our analyses revealed
that phosphoproteome dynamics precede ordered waves of
epigenomic, transcriptomic, and proteomic changes (Figures
2D and S4). Notably, about 50% of the regulated phosphosites
are significantly modified within 15 min of EpiLC induction, and
about one-third were altered as early as 5 min (Figures 2D and
S4A). By comparison, <1% of the transcriptome or proteome
undergo significant changes within the first hour (Figures S4B
and S4C). H3K4me3 levels at gene promoters began to change
an hour into EpiLC induction, offering the first indication of
changes to the epigenome, accompanied by gradual and wide-
spread changes to the transcriptome (Figure 2D). While the tran-
scriptome is significantly altered by the sixth hour, widespread
changes to the proteome were not evident until about 12 h
post induction (Figures 2D, S4B, and S4C), presumably because
of the latencies associated with protein synthesis and matura-
tion. These data suggest a pioneering role for signaling in plurip-
otent state transitions.
Widespread Changes to the Phosphoproteome Mark
ESC Transition from Ground-State Pluripotency
We next examined the magnitude of changes to dynamically
regulated phosphosites, transcripts, and proteins. Our analysis
revealed that protein phosphorylation undergoes the greatest
degree of change (3.2median-fold), followed bymRNAs (2.2me-
dian-fold) and proteins (1.8 median-fold) (Figures 2E and S4).
The broader distribution of the magnitude of changes to the
phosphosites (Figure 2E) indicates that the phosphoproteome
is more dynamic than the proteome during this transition.
Systematic elucidation of differentially regulated phosphosites,
mRNAs, and proteins revealed that about half of the phospho-
proteome is dynamically regulated over the time course,
whereas only about a third of the proteome undergoes temporal
regulation (Figure 2F).
To understand the interplay between protein phosphorylation
dynamics and protein abundance, we considered genes whose
mRNA, protein, and/or phosphorylation levels were differentially
regulated. Our analysis revealed that in 28% (925/3,251) of
cases, changes at the protein level were associated with
significant changes in their phosphorylation level. Notably,among proteins whose abundance was altered, one out of eight
(407/3,251) is associated with a significant change to their phos-
phorylation but not mRNA level (Figure 2G), suggesting a poten-
tial role for phosphorylation in regulating the levels and perhaps
the activities of a substantial fraction of proteins, presumably by
modulating their stability and/or degradation. However, about
60% (1,386/2,385) of the proteins with regulated phosphoryla-
tion sites are not associated with significant changes at the
protein level, suggesting that phosphorylation and/or dephos-
phorylation of these sites may alternatively play a role in altering
protein activity, localization, conformation, or interactions.
Collectively, these data highlight that changes in the phospho-
proteome are rapid, acute, and more widespread than changes
in both the transcriptome and proteome and exemplifies the cen-
tral role that dynamic phosphorylation plays during the phased
progression of pluripotency from the naive to the primed state.
De Novo Reconstruction of Kinase-Substrate Networks
Reveals Insights into Signaling Cascades, Dynamics,
and Crosstalk
To elucidate the set of signaling events, their timing, and order in
which they occur as cells transition through various phases of
pluripotency, we sought to identify active kinases that underlie
signaling cascades. To this end, we used the CLUE algorithm
(Yang et al., 2015) to partition all phosphosites into 12 optimal
clusters based on their temporal profiles (Figures S5A and
S5B). Using known kinase-substrate annotations (Hornbeck
et al., 2012), we identified four of these clusters to be enriched
for substrates with known kinases: ERK/S6K/RSK, mTOR,
p38a, and AKT (Figures 3A, 3B, and S5B; Table S5). An indepen-
dent analysis of substrates with known kinases, using our kinase
perturbation analysis tool KinasePA (Yang et al., 2016b),
confirmed activation and/or inactivation of these same kinases
at various stages during the ESC to EpiLC transition (Figure S5C).
With the assumption that phosphosites with similar temporal
dynamics are more likely to be substrates of the same kinase(s),
we hypothesized that proteins containing the phosphosites
within each of these four clusters aremore likely to be associated
with the same signaling pathway. Consistent with this prediction,
pathway enrichment analysis of the proteins harboring phospho-
sites within each of the four clusters revealed enrichment of
biological processes strongly associated with the respective
kinases (Figure 3C).
Temporal profiles of the phosphosites within the four clusters
revealed the precise timing and order of phosphorylation and/or
dephosphorylation events underlying various signaling cas-
cades (Figure 3B). Notably, substrates within the ERK/S6K/
RSK cluster underwent acute phosphorylation within the first
5 min, which is expected and reassuring given that EpiLC induc-
tion involves release from ERK inhibition in addition to FGF
stimulation of ERK signaling (Figure 1A). Interestingly, however,
putative ERK substrates, which remained phosphorylated for
about an hour after EpiLC induction, reverted to their basal
(0 h) phosphorylation levels by about 6 h (Figure 3B), suggesting
that ERK signaling is inhibited within a few hours after EpiLC in-
duction. Indeed, examination of the phosphorylation dynamics
of kinases ERK1 and ERK2 revealed acute dephosphorylation
beginning at about an hour after induction (Figure 3D). Consis-
tent with our MS-based phosphoproteomics data, western blotCell Systems 8, 427–445, May 22, 2019 431
Figure 3. Characterization of Signaling Dynamics during ESC to EpiLC Transition and Prediction of Substrates for Key Kinases Involved
(A) Clustering of phosphosites based on their temporal dynamics. Four clusters (out of the twelve; see Figures S6A and S6B) enriched for known substrates of
ERK and S6K/RSK (blue), mTOR (green), p38a (orange), or AKT (purple) are shown. Select substrates are highlighted. p values, Fisher’s exact test.
(B) Heatmap representation of the data shown in (A).
(C) Gene ontology (GO) analysis of phosphoproteins represented in each of the four clusters in (A). Top five enriched GO categories (biological processes) are
shown. Select phosphoproteins within each group are highlighted at the top.
(legend continued on next page)
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analysis confirmed the transient activation of ERK1/2, with no
major changes occurring at the protein or mRNA levels (Figures
3E and 3F).
ERK signaling is known to be tightly controlled by negative
feedback loops, wherein ERK1/2 activity transcriptionally in-
duces specific ERK1/2 pathway inhibitors, such as dual-speci-
ficity MAPK phosphatases (DUSPs), Sprouty (Spry), and Spred
proteins, which in turn lead to inhibition and inactivation of
ERK1/2 (Caunt and Keyse, 2013; Lake et al., 2016; Ornitz and
Itoh, 2015). To assess whether such negative feedback loops
shape ERK1/2 signaling dynamics as ESCs transition out of
naive pluripotency, we examined the expression dynamics of es-
tablished negative regulators of ERK1/2 signaling.Within an hour
after EpiLC induction, we observed rapid induction of Dusp6 (an
ERK1/2-specific phosphatase), Spry4, and Spred1 (Figure 3G),
all downstream transcriptional targets of ERK1/2 signaling
(Lake et al., 2016; Lanner and Rossant, 2010). These changes
coincided with the acute dephosphorylation of ERK1/2 (Figures
3D and 3G), suggesting that ERK1/2 signaling is conceivably un-
der strict control of negative feedback loops as ESCs transition
from the ground state.
Given the transient activation of ERK1/2 signaling (Figures 3B
and 3D), we hypothesized that ERK1/2 signaling is perhaps
dispensable 6 h after EpiLC induction. To test this idea, we
added an inhibitor of the MEK/ERK pathway (PD0325901) into
the culture medium 6 h after EpiLC induction and assessed
expression changes of naive and primed pluripotency factors
at 48 h post induction. ERK1/2 inhibition, beginning at 6 h, had
no major effect on the induction of factors associated with
primed pluripotency or suppression of naive pluripotency factors
(Figure 3H). However, EpiLC induction in the presence of
PD0325901 severely affected both the induction of primed plu-
ripotency factors and the suppression of naive pluripotency fac-
tors (Figure 3H). Altogether, these data establish that while ERK
signaling is required to trigger the exit from ground-state naive
pluripotency, it is largely dispensable after about 6 h into EpiLC
induction.
Besides ERK1/2, p38 is another MAPK kinase whose known
and putative substrates are dephosphorylated within about an
hour after EpiLC induction (Figure 3B). Given that ERK1/2-
induced DUSP proteins are also known to dephosphorylate the
p38 family of MAPKs (Caunt and Keyse, 2013; Lake et al.,(D) Temporal dynamics of relative phosphorylation levels (compared to 0 h) of
quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS
(E) Western blot analysis of total and phosphorylated Erk1/2 during ESC to EpiL
(F) Temporal dynamics of relative protein and mRNA levels (compared to 0 h), as q
ESC to EpiLC transition. Error bars represent SEM.
(G) Same as in (F) but showing data for Dusp6, Spry5, and Spred1, all downstre
(H) RT-qPCR analysis of relative expression of genes associated with naive plurip
naive ESCs (0 h). During the ESC to EpiLC transition (0–48 h), cells were left untre
time period. Data, normalized to Actin, represents mean of n = 3 biological replic
(I) Violin plots showing the distribution of ensemble prediction scores of all profile
five kinases (S6K/RSK, ERK, mTOR, p38a, and AKT); kinases other than these fi
substrate pair was generated using a positive-unlabeled ensemble algorithm (Ya
(J) Sequence motifs enriched within predicted substrates for ERK, S6K/RSK, AK
2009), using precompiledmouse Swiss-Prot sequence composition as the referen
the experimental versus the reference set.
(K) Temporal profiles of predicted substrates for ERK, S6K/RSK, AKT, mTOR, or p
respectively.
See also Figure S5.2016; Lanner and Rossant, 2010), we examined the temporal dy-
namics of p38a phosphorylation. Within an hour of ERK1/2 acti-
vation, p38a phosphorylation levels decreased by about 4-fold
(Table S1), suggesting a role for ERK1/2-responsive factors in
negatively regulating other pathways, including the p38 MAPK
pathway.
ERK1/2-induced Spry and Spred proteins suppress ERK1/2
signaling, in a negative feedback loop, by inhibiting complex for-
mation between the adaptor protein Grb2 and the FGF receptor
substrate 2 (Frs2). Intriguingly, the FGF-mediated Grb2-Frs2
signal also regulates the PI3K-AKT pathway as well as other
MAPK pathways (p38, JNK) (Lanner and Rossant, 2010; Ornitz
and Itoh, 2015). Thus, it is conceivable that any Spry- and/or
Spred-mediated negative regulation of Grb2-Frs2 complex for-
mation also inhibits the PI3K-AKT pathway, which is distinct
from theMAPK pathways. Indeed, the phosphorylation of known
and putative Akt substrates decreased immediately upon
ERK1/2 activation (Figures 3A and 3B), consistent with pathway
crosstalk between ERK1/2 and PI3K-AKT (Mendoza et al., 2011).
In addition, withdrawal of LIF to induce EpiLCs (Figure 1A) and
subsequent loss of LIF-induced PI3K activation may also have
contributed to dephosphorylation of Akt substrates (Yu and
Cui, 2016).
Activation of the ERK1/2 pathway, as observed during early
stages of ESC transition from the ground state (Figures 3B, 3D,
and 3E), can also activate the mammalian target of rapamycin
complex 1 (mTORC1), an effector molecule downstream of Akt
(Mendoza et al., 2011). Active ERK1/2 phosphorylates p90 ribo-
somal protein S6 kinase (RSK), and together they phosphorylate
TSC2 of the TSC complex (which is at the crossroad of ERK1/2
and PI3K-AKT pathways), leading to the release of TSC inhibition
of the mTORC1 activity (Mendoza et al., 2011). Consistent with
this established link, we find that phosphorylation of known
and putative mTOR substrates follows ERK1/2 activation (Fig-
ures 3B and 3D). To test whether mTORC1 activity is essential
for ESC exit from the ground state, we induced EpiLCs in the
presence or absence of rapamycin, an inhibitor of mTOR that
specifically targets mTORC1, and assessed changes in the
expression of naive and primed pluripotency factors at 48 h
post induction. We detected no significant differences (Fig-
ure 3H), indicating that mTORC1 activity is not required for exit
from naive pluripotency. Taken together, these data fit existingErk2 (T183/Y185) and Erk1 (T203/Y205, during ESC to EpiLC transition, as
). Error bars represent SEM.
C transition. Histone H3 is used as loading control.
uantified using LC-MS/MS and RNA-seq respectively, of Erk2 and Erk1 during
am transcriptional targets of Erk1/2 signaling. Error bars represent SEM.
otent state (right) or post-implantation epiblasts in EpiLCs (48 h) compared to
ated or cultured in the presence of PD0325901 or rapamycin for the indicated
ates. Error bars represent SEM. *p < 0.05 (Student’s t test, two-sided).
d phosphosites indicating the likelihood of them being a substrate of one of the
ve were grouped into the ‘‘other’’ category. Ensemble score for each kinase-
ng et al., 2016a). Black crosses (‘‘x’’) represent previously known substrates.
T, mTOR, or p38a kinases. Motifs were identified using IceLogo (Colaert et al.,
ce set. The y axis represents the difference in the frequency of an amino acid in
38a kinases. Mean and the standard deviation are shown as line-plot and range,
Cell Systems 8, 427–445, May 22, 2019 433
Figure 4. Comparative Analysis of the Proteome and Transcriptome during ESC to EpiLC Transition
(A) Temporal dynamics of correlation (y axis) between fold-changes in protein (compared to 0 h data) and fold-changes in mRNA (compared to 0 h) over time
(x axis). See Figure S6B for the actual scatterplots showing correlation at various time points.
(B) Gene ontology (GO) analysis of genes upregulated or downregulated (at both protein and mRNA levels) at 72 h versus 0 h during ESC to EpiLC transition.
Select GO categories (biological processes) enriched among upregulated or downregulated genes are shown.
(C) Temporal dynamics of relative protein and mRNA levels (compared to 0 h) of select genes. Genes associated with naive pluripotent state (Esrrb, Tfcp2l1, and
Prdm14), primed pluripotent state (Dnmt3a andOtx2), and those whose expression is relatively stable during ESC to EpiLC transition (Jarid2 andOct4) are shown.
Error bars represent SEM.
(legend continued on next page)
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models of canonical pathways and provide insights into the
crosstalk between signaling pathways and their dynamics during
various phases of pluripotency.
Machine Learning Predicts Substrates for ERK1/2,
S6K/RSK, mTOR, AKT, and p38a
Our understanding of signaling pathways that control a vast ma-
jority of cell fate decisions is limited because in many cases only
a fraction of these pathways has been mapped, with many com-
ponents remaining to be discovered. Hence, we sought to iden-
tify hitherto unknown substrates for each of the key kinases
(ERK, S6K/RSK, mTOR, AKT, and p38a) that we had inferred
to be active at various time points during ESC exit from the
ground state. We extended our ensemble machine learning
algorithm (Yang et al., 2016a) that integrates known kinase
recognition motifs and temporal profiles of phosphosites to pre-
dict novel substrates for the five kinases of interest (see STAR
Methods). For each phosphosite and kinase pair, we generated
an ensemble prediction score in the range 0–1, indicating the
likelihood that the phosphosite is a substrate of that kinase.
Tabulation of phosphosites by their prediction scores, for each
kinase, revealed enrichment of known substrates atop the list
(Figure 3I), illustrating the effectiveness of our approach in recov-
ering known substrates.
Using a score cutoff of 0.75, we predicted substrates for ERK,
S6K/RSK, AKT, mTOR, and p38a kinases (Table S6). De novo
sequence analysis of predicted substrates identified consensus
sequence motifs (Figure 3J) resembling the consensus recogni-
tion motifs of the corresponding kinases (Hornbeck et al., 2012).
Despite the similarity between the temporal patterns of predicted
substrates for ERK and RSK/S6K (Figure 3K), which are known
to act on the same substrate and sometimes in concert (Men-
doza et al., 2011), the consensus sequence motifs derived
from their putative substrates are quite different. Conversely,
although the consensus motifs for predicted ERK and mTOR
substrates (or RSK/S6K and AKT substrates) are similar, their
temporal patterns are diametrically opposite. These findings
illustrate the importance of integrating static features (such as
recognition motifs) with dynamic attributes (such as temporal
profiles of phosphosites) for successful prediction of novel
substrates.
Most signaling cascades culminate in the activation of down-
stream transcription regulators controlling gene expression pro-
grams. Hence, we asked whether transcription regulators, in
general, are enriched for dynamically regulated phosphosites.
Using the list of annotated transcription regulators (transcription
factors [TFs], co-factors, and chromatin remodeling enzymes)
(Zhang et al., 2012), we found that transcription regulators are
more likely to contain dynamically regulated phosphosites than
other proteins (odds ratio = 1.91; p = 2.13 1015; Fisher’s exact(D) Correlation between changes in protein andmRNA levels (y axis) for individual
(mRNA or protein) expression (72 h versus 0 h) (see STAR Methods). Genes t
(positioned to the left) and those that were substantially upregulated have higher
naive pluripotent state (ESCs), that are downregulated during EpiLC induction are
(EpiLCs), which are upregulated during EpiLC induction are highlighted as filled
entiation are highlighted as filled yellow circles. Prdm14, whose protein levels ar
highlighted as an open circle.
See also Figure S6.test), suggesting that protein phosphorylation/dephosphoryla-
tion could be a general mechanism for modulating the activity
of transcription regulators that mediate signal transduction dur-
ing the pluripotency progression.
To elucidate transcription and chromatin regulators that
mediate signaling cascades during the ESC to EpiLC transition,
we filtered our list of predicted substrates for known TFs,
co-factors, and chromatin-modifying enzymes and identified
several transcription regulators as putative substrates and
possible downstream effectors of ERK, S6K/RSK, mTOR, AKT,
or p38a signaling (Figure S5D; Table S6). Notably, ERK1/2 is pre-
dicted to phosphorylate key transcriptional regulators including
Lin28a (RNA binding protein), Zscan4c (expressed transiently
in 2-cell embryos and ESCs), EP300 (histone acetyltransferase),
Mta3 (member of the Mi2-NuRD histone deacetylase complex)
and JunD. Phosphorylation of predicted Lin28a phosphosite
(S200) by ERK was recently shown to be an important link be-
tween ERK signaling, post-transcriptional gene regulation, and
cell fate control (Tsanov et al., 2017). Predicted substrates of
mTOR include several chromatin remodeling enzymes with
known roles in ESC biology: Jarid2 and Eed (members of the pol-
ycomb repressive complex PRC2), Smarca4/Brg1 (the ATPase
subunit of the esBAF chromatin remodeling complex), Ino80
(the ATPase subunit of the INO80 chromatin remodeling com-
plex), and Kdm5b (histone H3K4 demethylase). S6K/RSK and
AKT are predicted to phosphorylate histone H3K9 demethylase
Kdm3b and Dnmt3b, respectively.
Comparative Analysis of Changes to the Transcriptome
and Proteome during Pluripotency Progression
The relationship between mRNA and protein levels is indicative
of the combined outcomes of transcription, mRNA stability,
translation, and protein degradation (de Sousa Abreu et al.,
2009). To understand the downstream effects of signaling on
the transcriptome and the extent to which changes at the tran-
script level during ESC to EpiLC transition translate to changes
at the protein level, we examined the temporal dynamics of
mRNA expression and protein abundance. To determine the
extent to which mRNA expression captures protein abundance
as ESCs transition out of ground-state pluripotency, we as-
sessed the concordance between steady-state mRNA and
protein levels at various time points during EpiLC induction. In
agreement with previous studies, which have found a generally
limited correlation between steady-state mRNA and protein
levels in mammalian systems (Schwanh€ausser et al., 2011), we
found correlation between these layers to be rather moderate
and stable across all time points (Pearson, R = 0.48–0.56) (Fig-
ure S6A). However, the correlation between changes in mRNA
levels and changes in protein levels (compared to 0 h) increased
from almost non-existent at 1 h to moderately high over timegenes plotted against their relative rank order (x axis) in terms of change in gene
hat were substantially downregulated at 72 h versus 0 h have smaller ranks
ranks (right). Select transcriptional and chromatin regulators, associated with
highlighted as filled red circles; those, associated with primed pluripotent state
blue circles. Genes whose expression is relatively stable during EpiLC differ-
e relatively stable but whose mRNA levels are dramatically downregulated, is
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(Figures 4A and S6B), suggesting that while absolute mRNA
levels may not be predictive of protein abundance, changes in
transcript level in a perturbed system over a period of time
more closely reflect changes in protein abundance.
Gene Ontology (GO) analysis of the genes that were downre-
gulated at both protein and mRNA levels at 72 h versus 0 h
revealed enrichment for those associated with stem cell mainte-
nance, blastoderm segmentation, and embryo implantation (Fig-
ure 4B). In contrast, upregulated genes were enriched for those
with roles in development and methylation-dependent chro-
matin silencing (Figure 4B), consistent with significant upregula-
tion of de novo DNAmethyltransferases Dnmt3a/b/l (Figures 4C,
4D, and S6C). Rank ordering of genes based on the extent of
fold-changes at the protein and mRNA levels revealed that
dynamically regulated genes, including those associated
with naive pluripotent state (e.g., Esrrb, Tfcp2l1, Nanog, Sox2,
Klf2/4, Tbx3, and Kdm3a/b) and post-implantation epiblasts
(e.g., Otx2, Dnmt3a/b, Zic2, Lin28a, and Lef1), exhibit strong
correlation (R > 0.85) between changes to the transcript and pro-
tein levels (Figures 4C, 4D, S6C, and S6D; Table S7). Intriguingly,
Prdm14, which is expressed in ICM (Yamaji et al., 2008) and
downregulated during EpiLC transition (Hayashi et al., 2011;
Yamaji et al., 2013), is a notable exception with substantial
change at the mRNA but not protein level (Figure 4C; Table
S7). Consistent with our RNA-seq and MS-based proteomic
data, qRT-PCR and western blot analyses confirmed that while
Prmd14 mRNA level decreases by 1,000-fold, its protein level
remains unchanged (Figures S1A and S6E). Genes whose
expression is known to be relatively stable during ESC to EpiLC
transition (e.g., Oct4 and Dnmt1) undergo minimal changes and
thus exhibit a weak correlation (Figures 4C, 4D, and S6C).
Distinct Waves of Global Proteomic Changes Mark
Discrete Phases of Pluripotency
Fuzzy c-means clustering of the temporal profiles of proteins that
were down- and upregulated during the ESC to EpiLC transition
revealed a dynamic transposition of cell identity, involving at
least three major waves of changes (Figure 5A; Table S8). The
first wave, presumably induced by upstream signaling events,
occurs at about 1 h into EpiLC induction and involves downregu-
lation of naive pluripotency TFs including Nanog and Tfcp2l1,
both immediate downstream targets of LIF/Stat3 signaling
(Niwa et al., 2009), and upregulation of epiblast-associated fac-
tors including Otx2, Zic2, Dnmt3l, and Lin28a. The second wave,
at 6–24 h, is characterized by downregulation of TFs specific to
the naive pluripotent state and pre-implantation development
(Esrrb, Sox2, Tbx3, Nr0b1, and Klf2/4/5), coupled with upregula-
tion of Dnmt3a/b. The third wave coincides with exit from the
naive pluripotent state, at around 36 h, when the cells enter an
irreversible phase on their way to establishing a post-implanta-
tion EpiLC identity.
Chromatin dynamics at the promoters of Esrrb and Otx2
exemplify changes to the epigenome and associated transcrip-
tional output (Figures 5B and 5C), which precede changes to
the proteome. Downregulation of Esrrb transcript and transcrip-
tion-dependent histone modifications (H3K4me3 and H3K27ac)
is evident as early as 1 h after EpiLC induction (Figure 5B). Rapid
loss of Esrrb transcription is correlated with marked reduction
in RNAPII levels at its promoter and is followed by the gain436 Cell Systems 8, 427–445, May 22, 2019of repressive H3K27me3 and H3K9me2 to maintain the
repressed transcriptional state. The converse is observed for
Otx2, wherein loss of H3K27me3 precedes RNAPII recruitment
and transcription.
H3K9me2 is known to recruit DNAmethyltransferases and is a
precursor to DNA methylation (Este`ve et al., 2006; Tachibana
et al., 2008). Downregulation of H3K9 demethylases (Kdm3a/b)
(Figure S6C) coupled with global increase in H3K9me2 levels
(Figure 5C) and upregulation of Dnmt3a/b/l (Figures 4C and
S6C) suggest a finely choreographed sequence of events pre-
ceding eventual epigenetic silencing of naive pluripotency fac-
tors by DNA methylation. Together, these data shed light on
the tightly orchestrated temporal regulation of gene expression
programs that coordinate the transition from naive to primed
pluripotency.
Identification of Cell-Surface Marker Proteins
Characteristic of Various Phases of Pluripotency
While transgenic reporters can be used to isolate cell popula-
tions, cell-surface markers allow for prospective identification
and tracking of cell types. Given the deep coverage of the
quantifiable proteome, we next sought to identify cell-surface
proteins characteristic of various phases of pluripotency as
ESCs transition from the ground state. Across the profiled
time points, we identified 78 cell-surface proteins, represent-
ing 20% of all cell-surface proteins (Gray et al., 2015), whose
expression was quantified with high confidence. Of these 78
cell-surface proteins, 49 were differentially expressed at one
or more profiled time points during the ESC to EpiLC transi-
tion, of which 34 were at least 3-fold differentially expressed
between naive ESCs (0 h) and EpiLCs (72 h) (Figure 6A).
Most of these cell-surface proteins exhibit concordant
changes in their transcript levels (Figure S7A), suggesting
that changes in their transcript levels account for much of
the differences in their protein levels. A majority of these
cell-surface proteins undergo a dramatic transformation in
their expression status at around 24–36 h post-EpiLC induc-
tion (Figure S7A), presumably coinciding with when the
cells exit the naive pluripotent state to acquire post-
implantation epiblast-like identity. These data suggest that
the cell-surface proteins captured in our proteomic dataset
can help discriminate pluripotent cells from pre- and post-im-
plantation epiblast of early mouse embryos.
To validate our proteomic data and to define a set of cell-sur-
face markers that can discriminate between naive ESCs and
EpiLCs, we performed flow cytometry analysis of candidate
cell-surface proteins for which antibodies suitable for flow
cytometry were commercially available. Our analysis of individual
markers with fluorescence-conjugated antibodies revealed a
good separation in fluorescence signal between naive ESCs
and EpiLCs (Figures 6B and 6C). Consistent with our MS-based
proteomic data, CD38 (Adprc1), CD105 (Eng), CD54 (Icam1),
CD9, CD146 (Mcam), CD81, and CD205 (Ly75) expression levels
are uniformly high in naive ESCs and low in EpiLCs. Conversely,
CD326 (Epcam), CD317 (Bst2), andCD90.2 (Thy1.2) are detected
at higher levels in EpiLCs compared to naive ESCs. Furthermore,
flow cytometry analysis of these cell-surface proteins during ESC
to EpiLC transition revealed that the expression dynamics of
individual cell-surface proteins faithfully track the phased
Figure 5. Distinct Waves of Global Changes in the Proteome Mark Various Phases of Pluripotency
(A) Temporal profiles of standardized changes in protein levels (compared to 0 h). Top and bottom 20%of the proteins that are themost down- or upregulated (red
and blue, respectively), based on the rank ordering in Figure 4D, are grouped into clusters based on fuzzy c-means clustering (c = 9). Top six clusters, with the
most proteins, are shown. Transcriptional and chromatin regulators, known or implicated to play important roles in ESCs and/or EpiLCs, are highlighted.
(B) Genome browser shots of Esrrb and Otx2 showing temporal profiles of gene expression dynamics (RNA-seq) and ChIP-seq read density profiles for RNAPII
and histone modifications H3K4me1, H3K4me3, H3K27ac, H3K27me3, and H3K9me2. Gene annotation is shown at the bottom, with an arrow representing the
direction of transcription from the active transcription start site. Regions containing transcriptionally active promoter and known enhancer are highlighted in
yellow and green, respectively.
(C) Temporal profiles of gene expression, RNAPII, and histone modification dynamics of genes associated with naive (ESCs) and primed state (EpiLCs). The top
and bottom 20%of the genes that are themost down- or upregulated, based on the rank ordering in Figure 4D, were considered as naive and primed state genes,
respectively. Median and standard deviation are shown as line-plot and range, respectively. ChIP-seq read density within the promoter region was used for
analysis (RNAPII, H3K4me3, and H3K27ac: ±1 Kb of TSS; H3K4me1, H3K27me3, and H3K9me2: ±2.5 Kb of TSS).progression of pluripotency, albeit each protein exhibiting
different dynamics during the 72-h time course (Figures S7B
and S7C). For example, high levels of CD105 andCD38 persisted
until 24 h before undergoing downregulation, whereas downre-
gulation of CD54 was more continuous through the time course.Conversely, while CD326 expression increased gradually over
time, upregulation of CD90.2 was not evident until 24 h.
Flow cytometry analysis of multiplexed cell-state-specific an-
tibodies showed that combinations of the antibodies can effec-
tively distinguish between naive ESCs and EpiLCs (Figures 6DCell Systems 8, 427–445, May 22, 2019 437
Figure 6. Cell-Surface Markers Specific to Naive and Formative/Primed Pluripotent States
(A) Scatterplot showing expression levels of cell-surface proteins in naive ESCs (x axis) versus EpiLCs (y axis). Data for 49 surface proteins that are differentially
expressed at one or more profiled time points during the ESC to EpiLC transition are shown. Based on their distance relative to the diagonal (expressed equally in
(legend continued on next page)
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and S7D). For example, high levels of CD105 and CD38 (or
CD54), characteristic of naive ESCs (Figure 6D), can serve as
excellent markers to identify and isolate naive ESCs from a
heterogeneous population of pluripotent cells. In addition, a
combination of CD105 (or CD54) and CD326, with discordant
expression pattern during ESC to EpiLC transition (Figures
S7B and S7C), can be useful for tracking the phased progression
of pluripotency as ESCs transition from the ground state toward
the primed state (Figure 6D). Altogether, these analyses allowed
us to identify a robust set of cell-state-specific surface proteins,
such as CD38, CD105, CD54, CD205, CD10 (Mme), CD26
(Dpp4), CD117 (Kit), and CD322 (Jam2) in naive ESCs and
CD317, CD326, CD90.2, and CD276 in EpiLCs (Figure 6E).
Comparative Analysis of Mouse and Human Pluripotent
States
While some cell-surface markers specific to ‘‘naive’’ hESCs, such
asCD77 (A4galt) andCD130 (Il6st) (Collier et al., 2017), are alsoex-
pressed in naive mouse ESCs (Figure S7E), we found it intriguing
that several cell-surface markers specific to the naive mouse
ESCs (including CD38, CD105, CD205, CD10, CD26, and
CD117) are not expressed in ‘‘naive’’ hESCs at the mRNA (Fig-
ure 6E) or protein levels (Collier et al., 2017). Similarly, CD75
(St6gal1), a marker specifically expressed in ‘‘naive’’ but not
primed hESCs (Collier et al., 2017), is lowly expressed in naive
mouse ESCs compared to EpiLCs or EpiSCs (Figure S7E). Moti-
vated by this lack of concordance, we asked whether the pur-
ported naive hESCs can be considered equivalent to naivemouse
ESCs. If not, this is of interest because hESCs might represent a
pluripotent state equivalent to an intermediate cell state between
the naive and the primed pluripotent states in mice. To address
this question, we compared the transcriptional states of conven-
tional hESCs, considered to be equivalent tomouse EpiSCs (Ros-
sant and Tam, 2017), and hESCs reset to a putatively naive state
(Chanetal., 2013;Takashimaetal., 2014) to thoseofmouseplurip-
otent cells at various time points during the naive ESC to EpiLC
timecourse; aspointsof reference,wealso includeddata fromhu-
manblastocyst ICM (Yanet al., 2013), E5–E7humanpre-implanta-
tion epiblast (Blakeley et al., 2015; Petropoulos et al., 2016), E5.5
mouse post-implantation epiblast (Boroviak et al., 2015), mouse
EpiSCs (Factoretal., 2014;Fiorenzanoetal., 2016),mouseEpiSCs
reset to a naive-like state (Takashima et al., 2014), EpiLCs (Chen
et al., 2018), and conventional mouse ESCs grown in media con-
taining serum+LIF (Fiorenzano et al., 2016; Marks et al., 2012),
PD03+LIF (Takashima et al., 2014), or serum+2i+LIF (Chen
et al., 2018).
PCA and unsupervised hierarchical clustering revealed
distinct clusters of cells corresponding to various pluripotentboth cell types), cell-surface proteins have been categorized as naive specific or p
expression dynamics during ESC to EpiLC transition.
(B and C) Histograms of flow cytometry analysis using fluorophore-conjugated a
(red) and EpiLCs (blue). Data for cell-state-specific proteins in naive ESCs (B) an
(D) Flow cytometry contour plots and dot plots of pairwise antibody combinations
columns).
(E) Relative gene expression of selected cell-surface proteins in mouse and huma
this study (0 h, 1 h, 6 h, 12 h, 24 h, 36 h, 48 h, and 72 h), RNA-seq data frommouse
(hESCs) and reset ‘‘naive’’ hESCs (Takashima et al., 2014). To facilitate direct co
changes relative to expression in mouse EpiSCs are shown.
See also Figure S7.states (Figures 7A and 7B). With much of the variation (35%)
captured in the first principal component (PC1), PC1 primarily
discriminates between naive and primed pluripotent states. Con-
ventional hESCs, generally considered as primed (Rossant and
Tam, 2017), clustered alongside EpiSCs, considered archetypal
representative of primed pluripotency (Rossant and Tam, 2017;
Smith, 2017). Interestingly, reset hESCs, reprogrammed to
closely resemble mouse naive ESCs, did not cluster anywhere
near naive mouse ESCs, although they clustered alongside cells
from human blastocyst ICM. A closer examination of naive
pluripotency-associated factors in reset hESCs revealed that
while the expression of some factors including Klf4, Klf5, Stella,
Prdm14, and Zfp42 was reset or upregulated to levels compara-
ble to those in naive mouse ESCs, many key factors including
Nanog, Esrrb, Nr0b1, Nr5a2, Tfcp2l1, and Klf2 were not
upregulated to appropriate levels (Figure 7C). Conversely, the
expression of many post-implantation epiblast-associated or
lineage-specific genes including Dnmt3a, Dnmt3b, Lin28a,
Krt18, Sox4, and mir-302b was not fully downregulated in reset
hESCs (Figure 7D). Together, these data suggest that while
chemical and/or genetic manipulation of primed hESCs induces
molecular features of naive pluripotency in hESCs, reset hESCs
are not identical to naive mouse ESCs.
DISCUSSION
Through integrative analysis of the proteome, phosphopro-
teome, transcriptome, and epigenome of ESCs transitioning
from naive to primed pluripotency, we have elucidated the
sequence of molecular events that underlie the phased progres-
sion of pluripotency. Our data provide new insights into the
multi-layered control of developmental transformation from
pre- to post-implantation epiblast differentiation and will serve
as a rich resource for further investigation of themechanisms un-
derlying ICM to post-implantation epiblast differentiation.
While previous studies haveprovided important insights into the
proteomes and phosphoproteomes of ESCs inmice (Christoforou
et al., 2016; Li et al., 2011; Nagano et al., 2005; Pines et al., 2011)
and human (Brill et al., 2009; Rigbolt et al., 2011; Swaney et al.,
2009; Van Hoof et al., 2009), signaling dynamics that underlie
pluripotent state transitions remain unexplored. Deeper coverage
of the proteome and the phosphoproteome, coupled with high
temporal resolution, allowed us to elucidate signaling dynamics
that underlie pluripotent state transitions. Our findings that rapid,
acute, and widespread changes to the phosphoproteome pre-
cede any changes to the epigenome, transcriptome, and prote-
ome highlight the prominent role signaling plays in cell fate deci-
sions during embryonic development.rimed specific (darker shades of red and blue, respectively). See Figure S7A for
ntibodies showing separation in the fluorescence signal between naive ESCs
d EpiLCs (C) are shown.
in ESCs and EpiLCs (first column) and over the ESC to EpiLC time course (other
n pluripotent cells based on RNA-seq data from ESC to EpiLC time course from
EpiSCs (Factor et al., 2014), and RNA-seq data from conventional human ESCs
mparison, all datasets were processed similarly and quantile normalized. Fold
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Figure 7. Comparative Analysis of Mouse and Human Pluripotent States
(A) PCA of RNA-seq data from this study (shades of gray; 0 h, 1 h, 6 h, 12 h, 24 h, 36 h, 48 h, and 72 h) and previously published studies (in color) (Blakeley et al.,
2015; Boroviak et al., 2015; Chan et al., 2013; Chen et al., 2018; Factor et al., 2014; Fiorenzano et al., 2016; Marks et al., 2012; Petropoulos et al., 2016; Takashima
et al., 2014; Yan et al., 2013). To facilitate direct comparison, all datasets were processed similarly and quantile normalized. Each data point represents a
biological replicate. mESC, mouse ESC; hESC, human ESC.
(B) Heatmap showing unsupervised hierarchical clustering of pairwise Pearson correlations between the RNA-seq datasets used in (A).
(C) Relative expression of genes associated with naive pluripotency. Fold changes relative to expression in mouse EpiSCs are shown.
(D) Same as in (C) but showing genes associated with formative and/or primed pluripotency.
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De novo reconstruction of kinase-substrate networks from our
phosphoproteomic data allowed us to elucidate signaling dy-
namics and provide insights into the crosstalk between various
signaling pathways during pluripotent state transitions. Consis-
tent with previous studies showing that ERK signaling is required
to induce ESCs to a state that is responsive to inductive cues
(Kunath et al., 2007), we found that ERK signaling is required
to trigger exit from ground-state naive pluripotency. What was
most revealing, however, was the acute dephosphorylation of
ERK and its substrates within about 6 h into EpiLC induction.
This, together with our finding that ERK signaling is largely
dispensable after about 6 h into EpiLC induction, suggests that
transitioning ESCs do not depend on ERK signaling beyond
the initial phase of exit from naive pluripotency and that the
timing and duration of the transient ERK activation are probably
under strict control during pluripotency progression. Indeed, a
recent study reported that genetic depletion or chemical inhibi-
tion of RSK1, an ERK substrate and a negative regulator of
ERK, is sufficient to increase levels of phosphorylated ERK1/2
and alter the kinetics of ESC differentiation (Nett et al., 2018).
Conversely, while short-term suppression of ERK signaling helps
maintain ESCs in an ICM-like naive state in vitro, prolonged sup-
pression of this pathway compromises the epigenetic and
genomic stability as well as the developmental potential of
ESCs (Choi et al., 2017).
We also found that mTORC1 activity is not required for exit
from naive pluripotency, consistent with studies showing that
mTORC1 activity is not required for cell fate transition (Bet-
schinger et al., 2013). However, inhibition of both mTORC1
and mTORC2 complexes has previously been shown to
induce reversible pausing of mouse blastocyst development
and ESCs in culture (Bulut-Karslioglu et al., 2016). Taken
together, these findings suggest a requirement for mTORC2
but not mTORC1 for exit from naive pluripotency.
Our analysis of the phosphoproteome data using a machine
learning approach allowed us to predict substrates for key
kinases that are active at various phases during pluripotency
progression. Our predictions include a number of transcription
and chromatin regulators, some of which, we surmise,
may have a potential role in mediating or modulating signaling
cascades controlling gene expression programs. Further
studies are required to validate the predicted substrates,
and determine their role, if any, in linking external signals to
epigenetic and/or transcriptional programs controlling cell
fate transition.
Deep coverage of the proteome, coupled with high temporal
resolution, allowed us to uncover distinct waves of global
changes to the proteome that mark discrete phases of pluripo-
tency. The initial wave of changes, likely triggered by the loss
of LIF/Stat3 signaling and/or activation of ERK signaling, marks
the onset of downregulation of key naive pluripotency factors
Nanog and Tfcp2l1 along with the activation of post-implantation
epiblast markers Otx2 and Zic2. This is immediately followed by
the second wave of changes characterized by downregulation of
other naivemarkers (Esrrb, Sox2, Tbx3, Nr0b1, Rex1, and Klf2/4/
5) and upregulation of Dnmt3a/b, setting the stage for rewiring of
the gene regulatory network and remodeling of the epigenome
(Buecker et al., 2014; Kurimoto et al., 2015; Shirane et al.,
2016). The final wave of changes, which coincides with the exitfrom the ground state, likely reflects the completion of the
dismantling of the naive pluripotency network and acquisition
of post-implantation epiblast identity. These findings shed the
first light on proteome-wide changes during the phased progres-
sion of pluripotency.
Because EpiLCs more closely resemble the early post-implan-
tation epiblast (E5.5–E6.5) than do EpiSCs (Hayashi et al., 2011),
they have been proposed to represent the ‘‘formative’’ pluripo-
tent state (Rossant and Tam, 2017; Smith, 2017), hypothesized
to be an intermediate state (between the naive and primed states)
that serves as the launching pad for multi-lineage differentiation
(Smith, 2017). Although EpiLC induction from ESCs is a direc-
tional and progressive process thatmirrors epiblast development
(Hayashi et al., 2011), the formative state characterized by
EpiLCs is transient and cannot be captured in stable self-renew-
ing cell lines using current culture conditions (Hayashi et al.,
2011). Given that ESCs exit the naive pluripotent state at about
36 h post EpiLC induction (Figure 2A) and that the transcriptome
of cells 72 h post EpiLC induction more closely resemble EpiSCs
(Figures 7A and 7B), we surmise that cells 36–48 h post EpiLC
induction are representative of the formative pluripotent state.
Our observation that Dnmt3l is transitorily expressed during
ESC to EpiLC transition (Figure 7D), coupled with its expression
in the epiblast (E4.5–6.5) (Smith et al., 2012) but not in EpiSCs
(Veillard et al., 2014), suggests that it could be an excellent
marker to isolate formative PSCs from a heterogeneous popula-
tion of pluripotent cells. It will be of future interest to determine
whether the formative phase can be captured as a stem cell state
in culture, as achieved for naive ESCs and EpiSCs.
Cell-surface proteins specific to ‘‘naive’’ and primed hESCs
are known (Collier et al., 2017), but surface markers specific to
the ground state, as in naive ESCs, remain to be characterized.
Our proteomic data allowed us to identify cell-surface proteins
that are specific to naive ESCs and EpiLCs. Flow cytometry anal-
ysis using a cohort of antibodies confirmed that the inferred
state-specific cell-surface markers accurately track pluripotent
state transitions, with individual proteins exhibiting different
temporal dynamics during the ESC to EpiLC transition. The iden-
tified cell-surface proteins can enable isolation of specific PSC
populations during ESC differentiation and induced PSC (iPSC)
reprogramming without having to rely on transgenic reporters.
Wewere surprised that several cell-surface proteins specific to
naive ESCs (CD38, CD105, CD205, CD10, CD26, andCD117) are
not expressed in ‘‘naive’’ hESCs (Collier et al., 2017), raising the
question of whether the purported naive hESCs can be consid-
ered equivalent to naive mouse ESCs. The naive pluripotent state
captured in mouse ESCs may be very transient or non-existent in
human embryos (Rossant and Tam, 2017). Given the lack of a uni-
versal criterion for testing naive pluripotency in a human system,
unlike murine ESCs where chimera contribution to blastocysts is
the benchmark, assigning naive status to reset or reprogrammed
hESCs is generally based on a molecular but not functional basis
(De Los Angeles et al., 2015; Hackett and Surani, 2014). Based on
the findings from our comparative analysis of the transcriptional
profiles of mouse and human pluripotent states (Figure 7), we
propose that the reprogrammed or reset hESCs are more similar
to the formative state EpiLCs than to the ground-state naive
mouse ESCs and probably lie somewhere along the develop-
mental axis between the naive and the formative state.Cell Systems 8, 427–445, May 22, 2019 441
In summary, our studies provide a comprehensive molecular
description of the phased progression of pluripotency. Our
data, togetherwith the complementary data describing sequence
of molecular events inherent to reprogramming somatic cells into
iPSCs (Cacchiarelli et al., 2015; Chronis et al., 2017; Polo et al.,
2012; Schwarz et al., 2018), provide a foundation for investigating
mechanisms that regulate pluripotent state transitions. The
general framework we employed to gain insights into the multi-
layered control of pluripotent cell fate transitions is a paradigm
that can readily be used to investigate any differentiation process.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Mouse ESC Culture and EpiLC Induction
d METHOD DETAILS
B Phosphoproteome Sample Preparation







B Phosphoproteomics Data Analysis
B Proteomics Data Analysis
B RNA-Seq Data Analysis
B ChIP-Seq Data Analysis
B Correlation Analysis of Protein and mRNA Expression
B Comparative Analysis of Multi-ome Dynamics
B Gene Ontology Analysis
B Kinase Activity Inference
B Pathway Enrichment Analysis
B Substrate Prediction and Motif Analysis
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
cels.2019.03.012.
ACKNOWLEDGMENTS
We thank Gaby Sowa, Igor Paron, and Korbinian Mayr for technical assistance
with MS measurement; Guang Hu for insightful discussion; and Xiaoling Li,
Carmen Williams, and Jothi lab members for critical comments on the
manuscript. This work was supported by the Intramural Research Program
of the NIH, National Institutes of Environmental Health Sciences (R.J.;
1Z1AES102625) and the Max-Planck Society for the Advancement of Science
(M.M.). P.Y. was supported by a Discovery Early Career Researcher Award
(DE170100759). S.J.H. was supported by an EMBO Long-Term Fellowship.
AUTHOR CONTRIBUTIONS
P.Y., S.C., and R.J. conceived the study; S.C. performed ESC-EpiLC and
RNA-seq experiments; S.J.H. performed phosphoproteomics and proteomics442 Cell Systems 8, 427–445, May 22, 2019experiments with input fromM.M.; R.P. performed fluorescence-activated cell
sorting (FACS) analyses; A.J.O. performed ChIP-seq experiments; P.Y. per-
formed data analysis with input from S.J.H., D.K., J.Y.H.Y., D.E.J., and R.J.;
D.K performed comparative transcriptome analysis ofmouse and human cells;
P.Y., D.P., and S.J.H. developed the data web server; and P.Y., S.J.H., S.C.,
M.M., and R.J. wrote the manuscript. All authors reviewed, edited, and
approved the final version of the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: November 13, 2018
Revised: February 12, 2019
Accepted: March 19, 2019
Published: May 8, 2019
REFERENCES
Aebersold, R., and Mann, M. (2016). Mass-spectrometric exploration of prote-
ome structure and function. Nature 537, 347–355.
Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq–a Python framework to
work with high-throughput sequencing data. Bioinformatics 31, 166–169.
Beck, S., Michalski, A., Raether, O., Lubeck, M., Kaspar, S., Goedecke, N.,
Baessmann, C., Hornburg, D., Meier, F., Paron, I., et al. (2015). The Impact
II, a Very High-Resolution Quadrupole Time-of-Flight Instrument (QTOF) for
Deep Shotgun Proteomics. Mol. Cell Proteomics 14, 2014–2029.
Betschinger, J., Nichols, J., Dietmann, S., Corrin, P.D., Paddison, P.J., and
Smith, A. (2013). Exit from pluripotency is gated by intracellular redistribution
of the bHLH transcription factor Tfe3. Cell 153, 335–347.
Blakeley, P., Fogarty, N.M., del Valle, I., Wamaitha, S.E., Hu, T.X., Elder, K.,
Snell, P., Christie, L., Robson, P., and Niakan, K.K. (2015). Defining the three
cell lineages of the human blastocyst by single-cell RNA-seq. Development
142, 3151–3165.
Boroviak, T., Loos, R., Bertone, P., Smith, A., and Nichols, J. (2014). The ability
of inner-cell-mass cells to self-renew as embryonic stem cells is acquired
following epiblast specification. Nat. Cell Biol. 16, 516–528.
Boroviak, T., Loos, R., Lombard, P., Okahara, J., Behr, R., Sasaki, E., Nichols,
J., Smith, A., and Bertone, P. (2015). Lineage-specific profiling delineates the
emergence and progression of naive pluripotency in mammalian embryogen-
esis. Dev. Cell 35, 366–382.
Brill, L.M., Xiong, W., Lee, K.B., Ficarro, S.B., Crain, A., Xu, Y., Terskikh, A.,
Snyder, E.Y., and Ding, S. (2009). Phosphoproteomic analysis of human em-
bryonic stem cells. Cell Stem Cell 5, 204–213.
Brons, I.G., Smithers, L.E., Trotter, M.W., Rugg-Gunn, P., Sun, B., Chuva de
Sousa Lopes, S.M., Howlett, S.K., Clarkson, A., Ahrlund-Richter, L.,
Pedersen, R.A., et al. (2007). Derivation of pluripotent epiblast stem cells
from mammalian embryos. Nature 448, 191–195.
Buecker, C., Srinivasan, R., Wu, Z., Calo, E., Acampora, D., Faial, T., Simeone,
A., Tan, M., Swigut, T., and Wysocka, J. (2014). Reorganization of enhancer
patterns in transition from naive to primed pluripotency. Cell Stem Cell 14,
838–853.
Bulut-Karslioglu, A., Biechele, S., Jin, H., Macrae, T.A., Hejna, M.,
Gertsenstein, M., Song, J.S., and Ramalho-Santos, M. (2016). Inhibition of
mTOR induces a paused pluripotent state. Nature 540, 119–123.
Cacchiarelli, D., Trapnell, C., Ziller, M.J., Soumillon, M., Cesana,M., Karnik, R.,
Donaghey, J., Smith, Z.D., Ratanasirintrawoot, S., Zhang, X., et al. (2015).
Integrative analyses of human reprogramming reveal dynamic nature of
induced pluripotency. Cell 162, 412–424.
Caunt, C.J., and Keyse, S.M. (2013). Dual-specificity MAP kinase phospha-
tases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 280,
489–504.
Chan, Y.S., Go¨ke, J., Ng, J.H., Lu, X., Gonzales, K.A., Tan, C.P., Tng, W.Q.,
Hong, Z.Z., Lim, Y.S., and Ng, H.H. (2013). Induction of a human pluripotent
state with distinct regulatory circuitry that resembles preimplantation epiblast.
Cell Stem Cell 13, 663–675.
Chen, A.F., Liu, A.J., Krishnakumar, R., Freimer, J.W., DeVeale, B., and
Blelloch, R. (2018). GRHL2-dependent enhancer switching maintains a plurip-
otent stem cell transcriptional subnetwork after exit from naive pluripotency.
Cell Stem Cell 23, 226–238.e4.
Choi, J., Huebner, A.J., Clement, K., Walsh, R.M., Savol, A., Lin, K., Gu, H., Di
Stefano, B., Brumbaugh, J., Kim, S.Y., et al. (2017). Prolonged Mek1/2 sup-
pression impairs the developmental potential of embryonic stem cells.
Nature 548, 219–223.
Christoforou, A., Mulvey, C.M., Breckels, L.M., Geladaki, A., Hurrell, T.,
Hayward, P.C., Naake, T., Gatto, L., Viner, R., Martinez Arias, A., et al.
(2016). A draft map of the mouse pluripotent stem cell spatial proteome.
Nat. Commun. 7, 8992.
Chronis, C., Fiziev, P., Papp, B., Butz, S., Bonora, G., Sabri, S., Ernst, J., and
Plath, K. (2017). Cooperative binding of transcription factors orchestrates re-
programming. Cell 168, 442–459.e20.
Colaert, N., Helsens, K., Martens, L., Vandekerckhove, J., and Gevaert, K.
(2009). Improved visualization of protein consensus sequences by iceLogo.
Nat. Methods 6, 786–787.
Collier, A.J., Panula, S.P., Schell, J.P., Chovanec, P., Plaza Reyes, A.,
Petropoulos, S., Corcoran, A.E., Walker, R., Douagi, I., Lanner, F., et al.
(2017). Comprehensive cell surface protein profiling identifies specific
markers of human naive and primed pluripotent states. Cell Stem Cell 20,
874–890.e7.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide pro-
tein quantification. Nat. Biotechnol. 26, 1367–1372.
Davidson, K.C., Mason, E.A., and Pera, M.F. (2015). The pluripotent state in
mouse and human. Development 142, 3090–3099.
De Los Angeles, A., Ferrari, F., Xi, R., Fujiwara, Y., Benvenisty, N., Deng, H.,
Hochedlinger, K., Jaenisch, R., Lee, S., Leitch, H.G., et al. (2015). Hallmarks
of pluripotency. Nature 525, 469–478.
de Sousa Abreu, R., Penalva, L.O., Marcotte, E.M., and Vogel, C. (2009).
Global signatures of protein and mRNA expression levels. Mol. Biosyst. 5,
1512–1526.
Dejosez, M., and Zwaka, T.P. (2012). Pluripotency and nuclear reprogram-
ming. Annu. Rev. Biochem. 81, 737–765.
Deutsch, E.W., Csordas, A., Sun, Z., Jarnuczak, A., Perez-Riverol, Y., Ternent,
T., Campbell, D.S., Bernal-Llinares, M., Okuda, S., Kawano, S., et al. (2017).
The ProteomeXchange Consortium in 2017: supporting the cultural change
in proteomics public data deposition. Nucleic Acids Res. 45, D1100–D1106.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,
P., Chaisson,M., andGingeras, T.R. (2013). STAR: ultrafast universal RNA-seq
aligner. Bioinformatics 29, 15–21.
Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., De Moor, B., Brazma, A., and
Huber, W. (2005). BioMart and Bioconductor: a powerful link between biolog-
ical databases and microarray data analysis. Bioinformatics 21, 3439–3440.
Este`ve, P.O., Chin, H.G., Smallwood, A., Feehery, G.R., Gangisetty, O., Karpf,
A.R., Carey, M.F., and Pradhan, S. (2006). Direct interaction between DNMT1
and G9a coordinates DNA and histone methylation during replication. Genes
Dev. 20, 3089–3103.
Factor, D.C., Corradin, O., Zentner, G.E., Saiakhova, A., Song, L., Chenoweth,
J.G., McKay, R.D., Crawford, G.E., Scacheri, P.C., and Tesar, P.J. (2014).
Epigenomic comparison reveals activation of ‘‘seed’’ enhancers during transi-
tion from naive to primed pluripotency. Cell Stem Cell 14, 854–863.
Fiorenzano, A., Pascale, E., D’Aniello, C., Acampora, D., Bassalert, C., Russo,
F., Andolfi, G., Biffoni, M., Francescangeli, F., Zeuner, A., et al. (2016). Cripto is
essential to capture mouse epiblast stem cell and human embryonic stem cell
pluripotency. Nat. Commun. 7, 12589.
Flicek, P., Amode, M.R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D.,
Clapham, P., Coates, G., Fairley, S., Fitzgerald, S., et al. (2012). Ensembl
2012. Nucleic Acids Res. 40, D84–D90.Gafni, O., Weinberger, L., Mansour, A.A., Manor, Y.S., Chomsky, E., Ben-
Yosef, D., Kalma, Y., Viukov, S., Maza, I., Zviran, A., et al. (2013). Derivation
of novel human ground state naive pluripotent stem cells. Nature 504,
282–286.
GeneOntology Consortium (2015). GeneOntology Consortium: going forward.
Nucleic Acids Res. 43, D1049–D1056.
Gray, K.A., Yates, B., Seal, R.L., Wright, M.W., and Bruford, E.A. (2015).
Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 43,
D1079–D1085.
Hackett, J.A., and Surani, M.A. (2014). Regulatory principles of pluripotency:
from the ground state up. Cell Stem Cell 15, 416–430.
Han, D.W., Tapia, N., Joo, J.Y., Greber, B., Arau´zo-Bravo, M.J., Bernemann,
C., Ko, K., Wu, G., Stehling, M., Do, J.T., et al. (2010). Epiblast stem cell sub-
populations represent mouse embryos of distinct pregastrulation stages. Cell
143, 617–627.
Hayashi, K., Ohta, H., Kurimoto, K., Aramaki, S., and Saitou, M. (2011).
Reconstitution of the mouse germ cell specification pathway in culture by
pluripotent stem cells. Cell 146, 519–532.
Heard, E., Rougeulle, C., Arnaud, D., Avner, P., Allis, C.D., and Spector, D.L.
(2001). Methylation of histone H3 at Lys-9 is an early mark on the X chromo-
some during X inactivation. Cell 107, 727–738.
Hornbeck, P.V., Kornhauser, J.M., Tkachev, S., Zhang, B., Skrzypek, E.,
Murray, B., Latham, V., and Sullivan, M. (2012). PhosphoSitePlus: a compre-
hensive resource for investigating the structure and function of experimentally
determined post-translational modifications in man and mouse. Nucleic Acids
Res. 40, D261–D270.
Huang, K., Maruyama, T., and Fan, G. (2014). The naive state of human plurip-
otent stem cells: a synthesis of stem cell and preimplantation embryo tran-
scriptome analyses. Cell Stem Cell 15, 410–415.
Huang, Y., Osorno, R., Tsakiridis, A., and Wilson, V. (2012). In vivo differentia-
tion potential of epiblast stem cells revealed by chimeric embryo formation.
Cell Rep. 2, 1571–1578.
Humphrey, S.J., Azimifar, S.B., and Mann, M. (2015). High-throughput phos-
phoproteomics reveals in vivo insulin signaling dynamics. Nat. Biotechnol.
33, 990–995.
Humphrey, S.J., Karayel, O., James, D.E., and Mann, M. (2018). High-
throughput and high-sensitivity phosphoproteomics with the EasyPhos plat-
form. Nat. Protoc. 13, 1897–1916.
Ishihama, Y., Rappsilber, J., andMann,M. (2006). Modular stop and go extrac-
tion tips with stacked disks for parallel and multidimensional peptide fraction-
ation in proteomics. J. Proteome Res. 5, 988–994.
Johnson, W.E., Li, C., and Rabinovic, A. (2007). Adjusting batch effects in
microarray expression data using empirical Bayes methods. Biostatistics 8,
118–127.
Kalkan, T., Olova, N., Roode, M., Mulas, C., Lee, H.J., Nett, I., Marks, H.,
Walker, R., Stunnenberg, H.G., Lilley, K.S., et al. (2017). Tracking the embry-
onic stem cell transition from ground state pluripotency. Development 144,
1221–1234.
Kojima, Y., Kaufman-Francis, K., Studdert, J.B., Steiner, K.A., Power, M.D.,
Loebel, D.A., Jones, V., Hor, A., de Alencastro, G., Logan, G.J., et al. (2014).
The transcriptional and functional properties of mouse epiblast stem cells
resemble the anterior primitive streak. Cell Stem Cell 14, 107–120.
Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N., and Mann, M. (2014). Minimal,
encapsulated proteomic-sample processing applied to copy-number estima-
tion in eukaryotic cells. Nat. Methods 11, 319–324.
Kunath, T., Saba-El-Leil, M.K., Almousailleakh, M., Wray, J., Meloche, S., and
Smith, A. (2007). FGF stimulation of the ERK1/2 signalling cascade triggers
transition of pluripotent embryonic stem cells from self-renewal to lineage
commitment. Development 134, 2895–2902.
Kurimoto, K., Yabuta, Y., Hayashi, K., Ohta, H., Kiyonari, H., Mitani, T.,
Moritoki, Y., Kohri, K., Kimura, H., Yamamoto, T., et al. (2015). Quantitative dy-
namics of chromatin remodeling during germ cell specification from mouse
embryonic stem cells. Cell Stem Cell 16, 517–532.Cell Systems 8, 427–445, May 22, 2019 443
Lake, D., Correˆa, S.A., and M€uller, J. (2016). Negative feedback regulation of
the ERK1/2 MAPK pathway. Cell. Mol. Life Sci. 73, 4397–4413.
Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and
memory-efficient alignment of short DNA sequences to the human genome.
Genome Biol. 10, R25.
Lanner, F., and Rossant, J. (2010). The role of FGF/Erk signaling in pluripotent
cells. Development 137, 3351–3360.
Li, Q.R., Xing, X.B., Chen, T.T., Li, R.X., Dai, J., Sheng, Q.H., Xin, S.M., Zhu,
L.L., Jin, Y., Pei, G., et al. (2011). Large scale phosphoproteome profiles
comprehensive features of mouse embryonic stem cells. Mol. Cell. Proteom.
10, M110.001750.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Marks, H., Kalkan, T., Menafra, R., Denissov, S., Jones, K., Hofemeister, H.,
Nichols, J., Kranz, A., Stewart, A.F., Smith, A., et al. (2012). The transcriptional
and epigenomic foundations of ground state pluripotency. Cell 149, 590–604.
Mendoza, M.C., Er, E.E., and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR
pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320–328.
Nagano, K., Taoka, M., Yamauchi, Y., Itagaki, C., Shinkawa, T., Nunomura, K.,
Okamura, N., Takahashi, N., Izumi, T., and Isobe, T. (2005). Large-scale iden-
tification of proteins expressed in mouse embryonic stem cells. Proteomics 5,
1346–1361.
Needham, E.J., Parker, B.L., Burykin, T., James, D.E., and Humphrey, S.J.
(2019). Illuminating the dark phosphoproteome. Sci. Signal. 12.
Nett, I.R., Mulas, C., Gatto, L., Lilley, K.S., and Smith, A. (2018). Negative feed-
back via RSK modulates Erk-dependent progression from naive pluripotency.
EMBO Rep. 19.
Nichols, J., and Smith, A. (2009). Naive and primed pluripotent states. Cell
Stem Cell 4, 487–492.
Niwa, H., Ogawa, K., Shimosato, D., and Adachi, K. (2009). A parallel circuit of
LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 460,
118–122.
Oldfield, A.J., Yang, P., Conway, A.E., Cinghu, S., Freudenberg, J.M.,
Yellaboina, S., and Jothi, R. (2014). Histone-fold domain protein NF-Y
promotes chromatin accessibility for cell type-specific master transcription
factors. Mol. Cell 55, 708–722.
Ornitz, D.M., and Itoh, N. (2015). The fibroblast growth factor signaling
pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215–266.
Pastor, W.A., Chen, D., Liu, W., Kim, R., Sahakyan, A., Lukianchikov, A., Plath,
K., Jacobsen, S.E., and Clark, A.T. (2016). Naive human pluripotent cells
feature a methylation landscape devoid of blastocyst or germline memory.
Cell Stem Cell 18, 323–329.
Petropoulos, S., Edsg€ard, D., Reinius, B., Deng, Q., Panula, S.P., Codeluppi,
S., Plaza Reyes, A., Linnarsson, S., Sandberg, R., and Lanner, F. (2016).
Single-cell RNA-seq reveals lineage and X chromosome dynamics in human
preimplantation embryos. Cell 165, 1012–1026.
Pines, A., Kelstrup, C.D., Vrouwe, M.G., Puigvert, J.C., Typas, D., Misovic, B.,
de Groot, A., von Stechow, L., van de Water, B., Danen, E.H., et al. (2011).
Global phosphoproteome profiling reveals unanticipated networks respon-
sive to cisplatin treatment of embryonic stem cells. Mol. Cell. Biol. 31,
4964–4977.
Polo, J.M., Anderssen, E., Walsh, R.M., Schwarz, B.A., Nefzger, C.M., Lim,
S.M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., et al. (2012). A molec-
ular roadmap of reprogramming somatic cells into iPS cells. Cell 151,
1617–1632.
Quinlan, A.R. (2014). BEDTools: the Swiss-army tool for genome feature anal-
ysis. Curr. Protoc. Bioinformatics 47, 11.12.1–11.12.34.
R Development Core Team (2016). R: A language and environment for statis-
tical computing (R Foundation for Statistical Computing).
Rigbolt, K.T., Prokhorova, T.A., Akimov, V., Henningsen, J., Johansen, P.T.,
Kratchmarova, I., Kassem, M., Mann, M., Olsen, J.V., and Blagoev, B.
(2011). System-wide temporal characterization of the proteome and phospho-
proteome of human embryonic stem cell differentiation. Sci. Signal. 4, rs3.444 Cell Systems 8, 427–445, May 22, 2019Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K.
(2015). Limma powers differential expression analyses for RNA-sequencing
and microarray studies. Nucleic Acids Res. 43, e47.
Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a
Bioconductor package for differential expression analysis of digital gene
expression data. Bioinformatics 26, 139–140.
Robles, M.S., Humphrey, S.J., and Mann, M. (2017). Phosphorylation is a cen-
tral mechanism for circadian control of metabolism and physiology. Cell
Metab. 25, 118–127.
Rossant, J., and Tam, P.P.L. (2017). New insights into early human develop-
ment: lessons for stem cell derivation and differentiation. Cell Stem Cell
20, 18–28.
Schwanh€ausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J.,
Chen, W., and Selbach, M. (2011). Global quantification of mammalian gene
expression control. Nature 473, 337–342.
Schwarz, B.A., Cetinbas, M., Clement, K., Walsh, R.M., Cheloufi, S., Gu, H.,
Langkabel, J., Kamiya, A., Schorle, H., Meissner, A., et al. (2018).
Prospective isolation of poised iPSC intermediates reveals principles of
cellular reprogramming. Cell Stem Cell 23, 289–305.e5.
Shahbazi, M.N., Scialdone, A., Skorupska, N., Weberling, A., Recher, G., Zhu,
M., Jedrusik, A., Devito, L.G., Noli, L., Macaulay, I.C., et al. (2017). Pluripotent
state transitions coordinate morphogenesis in mouse and human embryos.
Nature 552, 239–243.
Shirane, K., Kurimoto, K., Yabuta, Y., Yamaji, M., Satoh, J., Ito, S., Watanabe,
A., Hayashi, K., Saitou, M., and Sasaki, H. (2016). Global landscape and
regulatory principles of DNA methylation reprogramming for germ cell specifi-
cation by mouse pluripotent stem cells. Dev. Cell 39, 87–103.
Smith, A. (2017). Formative pluripotency: the executive phase in a develop-
mental continuum. Development 144, 365–373.
Smith, Z.D., Chan, M.M., Mikkelsen, T.S., Gu, H., Gnirke, A., Regev, A., and
Meissner, A. (2012). A unique regulatory phase of DNAmethylation in the early
mammalian embryo. Nature 484, 339–344.
Swaney, D.L., Wenger, C.D., Thomson, J.A., and Coon, J.J. (2009). Human
embryonic stem cell phosphoproteome revealed by electron transfer dissoci-
ation tandem mass spectrometry. Proc. Natl. Acad. Sci. USA 106, 995–1000.
Tachibana, M., Matsumura, Y., Fukuda, M., Kimura, H., and Shinkai, Y. (2008).
G9a/GLP complexes independently mediate H3K9 and DNA methylation to
silence transcription. EMBO J. 27, 2681–2690.
Takashima, Y., Guo, G., Loos, R., Nichols, J., Ficz, G., Krueger, F., Oxley, D.,
Santos, F., Clarke, J., Mansfield,W., et al. (2014). Resetting transcription factor
control circuitry toward ground-state pluripotency in human. Cell 158,
1254–1269.
Tesar, P.J., Chenoweth, J.G., Brook, F.A., Davies, T.J., Evans, E.P., Mack,
D.L., Gardner, R.L., and McKay, R.D.G. (2007). New cell lines from mouse
epiblast share defining features with human embryonic stem cells. Nature
448, 196–199.
Theunissen, T.W., Powell, B.E., Wang, H., Mitalipova, M., Faddah, D.A.,
Reddy, J., Fan, Z.P., Maetzel, D., Ganz, K., Shi, L., et al. (2014). Systematic
identification of culture conditions for induction and maintenance of naive hu-
man pluripotency. Cell Stem Cell 15, 471–487.
Tsanov, K.M., Pearson, D.S., Wu, Z., Han, A., Triboulet, R., Seligson, M.T.,
Powers, J.T., Osborne, J.K., Kane, S., Gygi, S.P., et al. (2017). LIN28 phos-
phorylation by MAPK/ERK couples signalling to the post-transcriptional
control of pluripotency. Nat. Cell Biol. 19, 60–67.
Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of micro-
arrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA
98, 5116–5121.
Tyanova, S., Temu, T., and Cox, J. (2016). The MaxQuant computational plat-
form for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11,
2301–2319.
Van Hoof, D., Mun˜oz, J., Braam, S.R., Pinkse, M.W., Linding, R., Heck, A.J.,
Mummery, C.L., and Krijgsveld, J. (2009). Phosphorylation dynamics during
early differentiation of human embryonic stem cells. Cell StemCell 5, 214–226.
Veillard, A.C., Marks, H., Bernardo, A.S., Jouneau, L., Lalo€e, D., Boulanger, L.,
Kaan, A., Brochard, V., Tosolini, M., Pedersen, R., et al. (2014). Stable methyl-
ation at promoters distinguishes epiblast stem cells from embryonic stem cells
and the in vivo epiblasts. Stem Cells Dev. 23, 2014–2029.
Ware, C.B., Nelson, A.M., Mecham, B., Hesson, J., Zhou, W., Jonlin, E.C.,
Jimenez-Caliani, A.J., Deng, X., Cavanaugh, C., Cook, S., et al. (2014).
Derivation of naive human embryonic stem cells. Proc. Natl. Acad. Sci. USA
111, 4484–4489.
Weinberger, L., Ayyash, M., Novershtern, N., and Hanna, J.H. (2016). Dynamic
stem cell states: naive to primed pluripotency in rodents and humans. Nat.
Rev. Mol. Cell Biol. 17, 155–169.
Wu, J., and Izpisua Belmonte, J.C. (2015). Dynamic pluripotent stem cell states
and their applications. Cell Stem Cell 17, 509–525.
Yamaji, M., Seki, Y., Kurimoto, K., Yabuta, Y., Yuasa, M., Shigeta, M.,
Yamanaka, K., Ohinata, Y., and Saitou, M. (2008). Critical function of
Prdm14 for the establishment of the germ cell lineage in mice. Nat. Genet.
40, 1016–1022.
Yamaji, M., Ueda, J., Hayashi, K., Ohta, H., Yabuta, Y., Kurimoto, K., Nakato,
R., Yamada, Y., Shirahige, K., and Saitou, M. (2013). PRDM14 ensures naive
pluripotency through dual regulation of signaling and epigenetic pathways in
mouse embryonic stem cells. Cell Stem Cell 12, 368–382.
Yan, L., Yang, M., Guo, H., Yang, L., Wu, J., Li, R., Liu, P., Lian, Y., Zheng, X.,
Yan, J., et al. (2013). Single–cell RNA-seq profiling of human preimplantation
embryos and embryonic stem cells. Nat. Struct. Mol. Biol. 20, 1131–1139.Yang, P., Humphrey, S.J., James, D.E., Yang, Y.H., and Jothi, R. (2016a).
Positive-unlabeled ensemble learning for kinase substrate prediction from
dynamic phosphoproteomics data. Bioinformatics 32, 252–259.
Yang, P., Patrick, E., Humphrey, S.J., Ghazanfar, S., James, D.E., Jothi, R.,
and Yang, J.Y. (2016b). KinasePA: phosphoproteomics data annotation using
hypothesis driven kinase perturbation analysis. Proteomics 16, 1868–1871.
Yang, P., Patrick, E., Tan, S.X., Fazakerley, D.J., Burchfield, J., Gribben, C.,
Prior, M.J., James, D.E., and Hwa Yang, Y. (2014). Direction pathway analysis
of large-scale proteomics data reveals novel features of the insulin action
pathway. Bioinformatics 30, 808–814.
Yang, P., Zheng, X., Jayaswal, V., Hu, G., Yang, J.Y., and Jothi, R. (2015).
Knowledge-based analysis for detecting key signaling events from time-series
phosphoproteomics data. PLoS Comput. Biol. 11, e1004403.
Ying, Q.L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J.,
Cohen, P., and Smith, A. (2008). The ground state of embryonic stem cell
self-renewal. Nature 453, 519–523.
Yu, J.S., and Cui, W. (2016). Proliferation, survival and metabolism: the role of
PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.
Development 143, 3050–3060.
Zhang, H.M., Chen, H., Liu, W., Liu, H., Gong, J., Wang, H., and Guo, A.Y.
(2012). AnimalTFDB: a comprehensive animal transcription factor database.
Nucleic Acids Res. 40, D144–D149.Cell Systems 8, 427–445, May 22, 2019 445
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
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Anti-CD105-APC Biolegend 120413; RRID:AB_2277915
Anti-CD146-PE-Cy7 Biolegend 134713; RRID:AB_2563108
Anti-CD205-PE Biolegend 359203; RRID:AB_2562438
Anti-CD317-APC Biolegend 127015; RRID:AB_1967101
Anti-CD326-Pac-Blue Biolegend 118225; RRID:AB_2563983
Anti-CD38-Pac-Blue Biolegend 102720; RRID:AB_10613468
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Anti-Erk1/2 Cell Signaling 9102; RRID:AB_330744
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Anti-H3K27ac Abcam ab4729; RRID:AB_2118291
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IRDye 680CW Goat anti-Rabbit IgG LI-COR Biotechnology 925-68021; RRID:AB_2713919
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Dynabeads (protein A) Pierce 88846
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Experimental Models: Cell Lines
Mouse ESCs (E14Tg2a) ATCC CRL-1821
Oligonucleotides
Primers used for RT-qPCR This paper Table S9
Deposited Data
Mouse ESCs (2i + LIF) 0h, RNA-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, RNA-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + 2i) 0h, RNA-Seq Kalkan et al., 2017 ArrayExpress: E-MTAB-5305
Mouse ESCs (N2B27) 16h, RNA-Seq Kalkan et al., 2017 ArrayExpress: E-MTAB-5305
Mouse ESCs (N2B27) 25h-Rex1high, RNA-Seq Kalkan et al., 2017 ArrayExpress: E-MTAB-5305
Mouse ESCs (N2B27), 25h-Rex1low, RNA-Seq Kalkan et al., 2017 ArrayExpress: E-MTAB-5305
Mouse ESCs (t2iL), RNA-Seq Takashima et al., 2014 ArrayExpress: E-MTAB-2857
Mouse ESCs (t2iL + Go¨), RNA-Seq Takashima et al., 2014 ArrayExpress: E-MTAB-2857
Mouse ESCs (PD03 + LIF), RNA-Seq Takashima et al., 2014 ArrayExpress: E-MTAB-2857
Mouse EpiSCs, RNA-Seq Factor et al., 2014;
Fiorenzano et al., 2016
GEO: GSE57409 and GSE79796
Mouse E5.5 postimplantation epiblast, RNA-Seq Boroviak et al., 2015 ArrayExpress: E-MTAB-2958
Human blastocyst ICM, RNA-Seq Yan et al., 2013 GEO: GSE36552
Human ESCs (hESCs), RNA-Seq Chan et al., 2013;
Takashima et al., 2014
ArrayExpress: E-MTAB-2031 and E-MTAB-2857
Reset hESCs (t2iL + Go¨), RNA-Seq Takashima et al., 2014 ArrayExpress: E-MTAB-2857
Human ESCs (hESCs, 3iL), RNA-Seq Chan et al., 2013 ArrayExpress: E-MTAB-2031
Human E5 epiblast, RNA-Seq Petropoulos et al., 2016 GEO: GSE74155
Human E6 epiblast, RNA-Seq Petropoulos et al., 2016 GEO: GSE74155
Human E7 epiblast, RNA-Seq Petropoulos et al., 2016 GEO: GSE74155
Human E6-E7 epiblast, RNA-Seq Blakeley et al., 2015 GEO: GSE66507
Mouse ESCs (2i + LIF) 0h, H3K4me1 ChIP-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
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Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, H3K4me1 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (2i + LIF) 0h, H3K4me3 ChIP-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, H3K4me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (2i + LIF) 0h, H3K27ac ChIP-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, H3K27ac ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (2i + LIF) 0h, H3K27me3 ChIP-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, H3K27me3 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (2i + LIF) 0h, H3K9me2 ChIP-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
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Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, H3K9me2 ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (2i + LIF) 0h, RNAPII ChIP-Seq This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, RNAPII ChIP-Seq
This paper GEO: GSE117896
Mouse ESCs (2i + LIF) 0h, Control input DNA This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 1h, Control input DNA
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 6h, Control input DNA
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 12h, Control input DNA
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 24h, Control input DNA
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 36h, Control input DNA
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 48h, Control input DNA
This paper GEO: GSE117896
Mouse ESCs (N2B27 + Activin A + bFGF +
1% KSR) 72h, Control input DNA
This paper GEO: GSE117896
Software and Algorithms
R 3.3.2 R Development Core Team, 2016 https://www.R-project.org/
MaxQuant 1.5.3.29 Cox and Mann, 2008 http://www.biochem.mpg.de/5111795/maxquant
Bowtie 0.12.8 Langmead et al., 2009 http://bowtie-bio.sourceforge.net/index.shtml
STAR 2.5.2a Dobin et al., 2013 https://github.com/alexdobin/STAR
Bedtools 2.26.0 Quinlan, 2014 http://bedtools.readthedocs.io/en/latest/
HTSeq 0.6.1 Anders et al., 2015 http://www-huber.embl.de/HTSeq/doc/overview.html
ComBat (SVA R package 3.24.0) Johnson et al., 2007 https://www.bu.edu/jlab/wp-assets/ComBat/
Abstract.html
Limma 3.32.2 Ritchie et al., 2015 https://bioconductor.org/packages/release/bioc/
html/limma.html
edgeR 3.16.5 Robinson et al., 2010 https://bioconductor.org/packages/release/bioc/
html/edgeR.html
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DESeq2 1.16.1 Love et al., 2014 https://bioconductor.org/packages/release/bioc/
html/DESeq2.html
Clue 1.2 Yang et al., 2015 https://CRAN.R-project.org/package=ClueR
directPA 1.3 Yang et al., 2014 https://CRAN.R-project.org/package=directPA
Kinase-substrate Prediction Yang et al., 2016a https://github.com/PengyiYang/KSP-PUEL
KinasePA Yang et al., 2016b http://shiny.maths.usyd.edu.au/KinasePA/
IceLogo Colaert et al., 2009 https://github.com/compomics/icelogoCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Dr. Raja Jothi (jothi@
nih.gov).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse ESC Culture and EpiLC Induction
Mouse ESCs (E14Tg2a; male) were grown in serum free N2B27-based medium, supplemented with 2i (MEK inhibitor PD0325901,
1.0 mM and Gsk3b inhibitor CHIR99021, 3.0 mM) and LIF (1000u/ml) in tissue culture (TC) plates coated with poly L-ornithine and
laminin (Hayashi et al., 2011). For EpiLC induction, ESCs, adapted for a minimum of 4 passages in 2i+LIF, were plated on TC dishes
coated with human plasma fibronectin (5mg/ml) in N2B27 medium containing activin A (20 ng/ml), bFGF (12mg/ml) and KSR (1%)
(Hayashi et al., 2011).
METHOD DETAILS
Phosphoproteome Sample Preparation
All MS experiments were performed in biological quadruplicates. Phosphopeptides were enriched using the EasyPhos workflow as
described previously (Humphrey et al., 2015). Briefly, cells were lysed in GdmCl buffer (6M Guanidine hydrochloride, 100 mM Tris
pH 8.5, 10mMTCEP, 40mM2-Chloroacetamide) and heated for 5min at 95C. Lysateswere cooled on ice for 15minutes, sonicated,
and acetone precipitated overnight by addition of 4X volumes of -20C acetone. Precipitated protein was collected by centrifugation,
and pellets washed 1X with 4 mL -20C 80% (v/v) acetone. Washed pellets were air-dried for 10 min at room temperature, resus-
pended in 500 mL TFE digestion buffer (10% TFE (2,2,2-Trifluroethanol), 100 mM ammonium bicarbonate), and sonicated (Bioruptor
(Diagenode), 4C for 2X 5 min cycles) until a homogenous suspension was formed. Protein concentration was determined by BCA
assay (Thermo Fisher Scientific). Aliquots corresponding to 1 mg protein were diluted to 500 mL in TFE digestion buffer for phospho-
peptide enrichment, and 20 mg protein was used for proteome analysis. Protein was subsequently digested by the addition of 1:100
LysC and Trypsin overnight at 37C with rapid agitation (2,000 rpm).
Proteome Sample Preparation
As with phosphoproteome, all MS experiments were performed in biological quadruplicates. In addition, to enhance coverage of the
proteome measurements, we pooled the four biological replicates from each time-point and performed StageTip-based Strong
Cation Exchange (SCX) fractionation (Ishihama et al., 2006) of this pooled sample for the proteome runs (Figures 1C, S2A, and
S2B). Proteome samples were processed using an in-StageTip (iST) protocol (Kulak et al., 2014), and 10 mg (or 20 mg) protein material
was used for single-shot or fractionated samples, respectively. For fractionated samples, equal quantities (5 mg per biological repli-
cate) of protein were pooled prior to digestion. Precipitated protein was reconstituted in iST lysis buffer (6M GdmCl, 100 mM Tris
pH 8.5), diluted to 10-fold in iST dilution buffer (10% acetonitrile, 25mMTris pH 8.5), and digested with 1:100 LysC (Wako Chemicals)
and Trypsin at 37C overnight directly in StageTips containing SDB-RPS (Styrene Divinyl Benzene Reverse Phase Sulfonate)
(3X plugs, Empore 3M) (iST-SDB-RPS) or Strong Cation Exchange (SCX) (6X plugs, Empore 3M) (iST-SCX), for single-shot or frac-
tionated samples respectively. For single-shot iST-SDB-RPS samples, StageTips were washed once with 100 mL 0.2% (v/v) Trifluro-
acetic acid (TFA), and subsequently eluted with 60 mL 5% (v/v) ammonium hydroxide, 80% (v/v) acetonitrile. For fractionated ist-SCX
samples, peptides were eluted in 5X fractions (50 mM, 75 mM, 125 mM, 200 mM, 300 mM) of ammonium acetate, 20% (v/v) Aceto-
nitrile, 0.5% (v/v) formic acid, followed by a final elution with 5% (v/v) ammonium hydroxide/80% (v/v) acetonitrile.
LC-MS/MS Measurement
Peptides and phosphopeptides were loaded onto a 40 cm column with a 75 mM inner diameter, packed in-house with 1.9 mM C18
ReproSil particles (Dr. Maisch GmbH), and column temperature was maintained at 50C using a homemade column oven. An
EASY-nLC 1000 system (Thermo Fisher Scientific) was interfaced with a Q Exactive HF benchtop Orbitrap mass spectrometerCell Systems 8, 427–445.e1–e10, May 22, 2019 e6
(Thermo Fisher Scientific) using a NanoSpray Flex ion source (Thermo Fisher Scientific). For all samples, peptides were separated
with a binary buffer system of 0.1% (v/v) formic acid (buffer A) and 60% (v/v) acetonitrile/0.1% (v/v) formic acid (buffer B), at a
flow rate of 300 nL/min. For phosphoproteome analysis peptides were eluted with a gradient of 5% - 25% buffer B over 85 minutes
followed by 25% - 55% buffer B over 45 minutes, and peptides were analysed with one full scan (300-1,600 m/z; R=60,000 at
200 m/z) at a target of 3e6 ions, followed by up to five data-dependent MS/MS scans with HCD (target 1e5 ions; max IT 120 ms;
isolation window 1.6m/z; NCE 25%; 40% underfill ratio), detected in the Orbitrap detector (R=15,000 at 200m/z). Dynamic exclusion
(40 s) and Apex trigger (4 to 7 s) were switched on. For single-run proteome analysis, peptides were eluted with a gradient of
4% - 32% buffer B over 180 minutes followed by 32% - 47% buffer B over 40 minutes, and for pooled SCX-fractionated samples,
peptides were elutedwith a gradient of 4% - 32%buffer B over 90minutes followed by 32% - 47%buffer B over 20minutes. Peptides
were analysed, with one full scan (300-1,600 m/z; R=60,000 at 200 m/z) at a target of 3e6 ions, followed by up to 10 (for single-run
samples) or 15 (for fractionated samples) data-dependent MS/MS scans with HCD (target 1e5 ions; max IT 100 ms for single-run
samples, 25 ms for fractionated samples; isolation window 1.6 m/z; NCE 25%; 30% underfill ratio), detected in the Orbitrap detector
(R=15,000 at 200 m/z). Dynamic exclusion (30 s) was switched on.
Quantitative RT-PCR
Quantitative RT-PCR was performed as previously described (Oldfield et al., 2014). Briefly, Total RNAs were prepared from cells
using Qiazol lysis reagent (Qiagen), and cDNAs were generated using the iScript kit (Bio-Rad) according to the manufacturer’s in-
structions. Quantitative PCRs were performed on the Bio-rad CFX-96 or CFX-384 Real-Time PCR System using the Bio-rad SsoFast
EvaGreen supermix. Three or more biological replicates were performed for each experiment. Data are normalized to Actin expres-
sion, and plotted as mean +/- S.E.M. See Table S9 for primers used in RT-qPCR analysis.
RNA-Seq
Total RNA was extracted with Qiazol lysis reagent (Qiagen) treatment and purified using miRNeasy Kit. The samples were then
treated with DNase I, Amplification grade (Invitrogen) and stranded libraries were prepared using the TruSeq stranded RNA kit
(Illumina) with RiboZero depletion (Gold kit) and sequenced on Illumina HiSeq system.
ChIP-Seq
ChIP was performed as previously described (Oldfield et al., 2014). Briefly, mouse ESCs (1x107) were cross-linked with 1% formal-
dehyde in DMEM for 10 min, and the reaction was quenched by the addition of glycine at a final concentration of 125 mM for 5 min.
Cells were washed twice with PBS, and resuspended in 1ml of lysis buffer A (50mMHEPES pH 7.5; 140mMNaCl; 1 mMEDTA; 10%
Glycerol; 0.5% IGEPAL CA-630; 0.25% Triton X-100; 1x Complete protease inhibitor mixture, 200 nM PMSF). After 10min on ice, the
cells were pelleted and resuspended in 1 ml of lysis buffer B (10 mM Tris-HCl pH 8.0; 200 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 1x
protease inhibitors, 200 nM PMSF). After 10 min at room temperature, cells were sonicated in lysis buffer C (10 mM Tris-HCl pH 8.0;
100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% sodium deoxycholate; 0.5% N-lauroylsarcosine; 1x protease inhibitors, 200 nM
PMSF) using Diagenode Bioruptor for 16 cycles (30 sec ON; 50 sec OFF) to obtain 200–500 bp fragments. Cell debris were pre-
cleared by centrifugation at 14,000 rpm for 20 min, and 8 mg (or 20 mg) of chromatin was incubated with antibodies against specific
Histone modifications (or RNA Pol II, respectively) overnight at 4 C. Protein A/G-conjugated magnetic beads (Pierce Biotech) were
added the next day for 2 hours. Subsequent washing and reverse cross-linking were performed as previously described (Heard
et al., 2001).
Western Blot
Western-blots were performed as previously described (Oldfield et al., 2014). Briefly, Cell pellets, lysed in RIPA buffer (25 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1% IGEPAL, 1% Sodium deoxycholate) with protease inhibitors, were sonicated using Bioruptor
(Diagenode) for three cycles (30 sec ON; 50 sec OFF). The lysate was boiled with SDS-PAGE sample buffer, loaded onto NuPAGE
gel, and transferred to 0.22 mM PVDF membranes. The membranes were pre-wet in 100%methanol and rinsed with ultrapure water
before being washed for 5 min in 1x PBS. The membranes were then blocked with Odyssey blocking buffer for 1 h at room temper-
ature with gentle shaking. Each membrane was treated with appropriate primary and secondary (IRDye) antibodies. The membranes
were then washed in PBS (0.1% Tween 20), rinsed with PBS and scanned and quantified on an Odyssey imaging system.
Flow Cytometry
Cells were dissociated into single cells with Accutase, washed and passed through 40 mmcell strainers. Cells were washed with PBS
and stained with LIVE/DEAD Fixable Near-IR dye (Invitrogen) to stain dead cells (1 x 106 to 2 x 106 cells per reaction). Cells were
washed 2X with flow buffer (2% FBS in PBS, 1MmEDTA, 25ug/ml Dnase I). Conjugated antibodies were mixed with 50 mL flow buffer
and applied to 50 mL of cells. Cells were incubated for 30 minutes at 4C in the dark and washed 2X with buffer (2% FBS in PBS) and
centrifuged at 300xg for 5 minutes. Data was analyzed using FlowJo V10 software or FACSDiva (BD Biosciences).
Phosphoproteomics Data Analysis
Raw MS files from phosphoproteomics experiments were processed using MaxQuant (version 1.5.3.29) (Cox and Mann, 2008) for
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are classified into Class I (27,381), II (6,265) and III (3,973) based onMaxQuant reported confidence of localization scores (Figure S2A,
left panel). Phosphorylation level of each site was quantified using LFQ intensity from MS and logarithm (base 2) transformed.
Denoting the 12 profiled time points as ti (i= 0, 5m, 15m, 30m, 1h, 3h, 6h, 12h, 24h, 48h, 72h) and the number of times a phosphor-
ylation sites (p) quantified at a given time point as qp(ti). Phosphorylation sites from Class I were filtered to require at least 4 valid
values in any one of the 12 time-points (i.e. d i such that qp(ti)=4). Subsequently, only phosphorylation sites with at least 12 out
of 48 quantified values (12 time-points, four replicates) were retained (i.e.
P
iq
pðtiÞR12) for further analysis. This resulted in
17,866 phosphorylation sites passing the above stringent filtering criteria. This filtered data was thenmedian-normalized with respect
to each of the 12 time-points and remaining missing quantifications within these data were subsequently imputed using a two-step
procedure. In the first step, for each phosphorylation site with two or more quantified values out of the four biological replicates in
each time point (i.e.d i such that qp(ti)R2), we calculated the mean (m
p
ti
) and standard deviation (sdpti ) for that p at ti using quantified
replicates and imputedmissing data for p at ti using a Gaussianmodel parameterised bym
p
ti
and sdpti . In the second step, we imputed
the remaining missing values using the heuristic random-tail method described previously (Robles et al., 2017). Specifically, for each
time point ti the grandmean (m
,
ti
) and grand standard deviation (sd,ti ) across all phosphorylation sites were calculated and a Gaussian
model were utilised to impute missing data in each ti by down-shifting m
,
ti
by 1.6 and with a standard deviation of sd,ti3 0.6. Phos-
phoproteomics data were subsequently corrected for batch effects usingComBat (Johnson et al., 2007), and finally data was normal-
ized by the total proteome.
Proteomics Data Analysis
Like the phosphoproteome data, raw MS files from total proteome experiments were processed using MaxQuant (1.5.3.29) for pro-
tein identification using mouse UniProt database (August 2015 release). After filtering to remove common protein contaminants and
reverse matches, we identified a total of 10,597 proteins. Protein abundance was quantified using LFQ intensity and log (base 2)
transformed. Since the fractionated samples have fewer missing values (Figures S2B and S2C), we took advantage of themore com-
plete quantitation from fractionated samples to guide the imputation of missing values in the single-run samples. Denoting the 9 pro-
filed time points in proteomics experiment as ti (i= 0, 30m, 1h, 3h, 6h, 12h, 24h, 48h, 72h) and a protein (P) that is quantified at a given
time point in the fractionated sample as sP(ti), protein identifications from fractionated samples were filtered to require at least 5 valid
values out of the 9 time-points (i.e.
P
is
PðtiÞR5). Then, for fractionated samples we calculated the means (mSti ) and the standard
deviations sdSti at each time point ti and imputed the missing values in the fractionated samples at each time point by downshifting
mSti by 1.8 and with a standard deviation of sd
S
ti
3 0.3 as in Beck et al. (2015). After filtering and imputing data specifically for fraction-
ated samples, we first calibrated the single-run samples with respect to fractionated samples at each time point and then imputed
missing values by using the means mSti and standard deviations sd
S
ti
30:3 calculated from fractionated samples. Then, batch effect
correction was applied using ComBat (Johnson et al., 2007 Biostatistics) for subsequent analysis. Fuzzy c-means clustering (c = 9)
was used to partition the proteins that are the most down-regulated or up-regulated into clusters based on their temporal expression
profiles (Figure 5A). Resulting clusters were ranked by the cluster size (number of proteins) from large to small, and the top six
clusters, with the most proteins, are shown (Figure 5A).
RNA-Seq Data Analysis
Pair-end 51 bp reads weremapped to themouse (mm9) genome using STAR (version 2.5.2a) (Dobin et al., 2013), allowing up to three
mismatches, retaining only reads that align to unique locations, and permitting a maximum intron length of 100,000. For visualization
on theUCSCGenomeBrowser and generation of screenshots,mapped readswere normalized to reads permillion (RPM) and plotted
as histograms usingBedtools version 2.26.0 (Quinlan, 2014). For gene expression analysis,mapped readswere subsequently used to
quantify Ensembl/Refseq transcript and gene models (Flicek et al., 2012) using HTSeq version 0.6.1 (Anders et al., 2015). Raw read
counts per gene were normalized using the DESeq2 R package version 1.16.1 (Love et al., 2014), batch effect corrected by ComBat,
and transformed using a regularized log function implemented in DESeq2. Gene length was extracted from BioMart Database (Dur-
inck et al., 2005), and edgeR package version 3.18.1 (Robinson et al., 2010) was used to calculate RPKM for each gene. RNA-Seq
data from Kalkan et al. (2017) were processed similarly (as described above) and normalized together with RNA-Seq data generated
for this study using DESeq2 to facilitate principal component analysis (PCA) (Figure 2A). For comparison of RNA-Seq data from
mouse and human cells (Figures 6E, 7C, and 7D), RPKM data for genes were log2 transformed (after adding 1) and quantile normal-
ized. For PCA and unsupervised hierarchical clustering of RNA-Seq data frommouse and human cells, only geneswith the samegene
symbol inmouse and human transcriptomeswere considered. After filtering out low-expression genes (mean expression (log2 RPKM)
across the eight ESC to EpiLC time-points < 1.5, a threshold that was empirically derived from the distribution ofmeans), coefficient of
variation for each gene was calculated as a measure of variability in gene expression. To explore the data in an unbiased manner, we
carried out dimensionality reduction using the top 1000 genes with the highest variability in expression (Figures 7A and 7B).
ChIP-Seq Data Analysis
Single-end 51 bp reads were mapped to the mouse (mm9) genome using Bowtie version 0.12.8 (Langmead et al., 2009), allowing
up to two mismatches, retaining only reads that align to unique locations. For visualization on the UCSC Genome Browser and
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version 2.26.0 (Quinlan, 2014). Enrichment of individual histone modifications (except for H3K9me2) or RNAPII at gene promoters
(Figure 1C) was called based on normalized ChIP-Seq read density within the promoter region (±2 Kb of TSS) compared to input
read density with the same region (>3-fold and FDR<0.01). For H3K9me2, given its broader footprint, ChIP-Seq read density within
gene body instead of the promoter was used. For PCA unsupervised hierarchical clustering of histonemodifications and RNAPII data
(Figures S3A and S3F), ChIP-Seq signal for were quantile normalized to account for differences in signal-to-noise ratios.
Correlation Analysis of Protein and mRNA Expression
Global correlation between protein and mRNA expression for each time-point (Figure S6A) was calculated using Pearson correlation
coefficient using only genes that were quantified at both the mRNA (log10 RPKM) and the protein level (log10 LFQ intensity). Global
correlation between protein andmRNA fold-changes (compared to 0h data) for each time-point was calculated similarly (Figure S6B)
and fitted using a local polynomial regression (Loess) model (Figure 4A). The correlation between mRNA and protein expression
across the time-course, for individual genes, was calculated using Pearson correlation coefficient (Figures 4C, 4D, and S6D). To
determine the relevance of each gene to ESCs and EpiLCs, we first rank-ordered the genes based on their mRNA (or protein)
fold-changes in EpiLC (72h) vs ESC (0h) and then obtained the final rank-ordering of the genes (Figures 4D and S6C) based on
the average of their two ranks (mRNA/protein expression-based).
Comparative Analysis of Multi-ome Dynamics
Differentially regulated mRNAs, proteins and phosphosites at one or more time points (compared to 0h data) were determined using
ANOVA test with multiple testing correction (FDR<0.01) (Figure S4). Volcano plots were used to visualize dynamic regulation by plot-
ting the log2 fold change against –log10 of the permutation FDR adjusted p-value of the t-test on each mRNA, protein and phospho-
site, respectively, at each time point. A scatter parameter of 0.1 (Tusher et al., 2001) which takes into account the log2 fold change and
the statistical significance was used to identify dynamically regulated mRNAs, proteins, and phosphosites, respectively, at each time
point. Percentage of dynamically regulatedmRNAs, proteins, phosphosites and enriched H3K4me3 and H3K27me3were calculated
for each time point and scaled to themaximumpercentage on transcriptome, proteome, phosphoproteome and epigenome layers. A
local polynomial regression (Loess) was fitted to the scaled percentage calculated for each time point (Figure 2D). Magnitude of
change for each mRNA, protein and phosphosite (Figure 2E) was determined by taking the highest absolute fold-change observed
at all time points (compared to 0 h data): maxðabsðxi=x0ÞÞ; i = 1.n;where xi (and x0) denotes the normalized value quantified at the ith
(or 0 h) time-point for each mRNA, protein, or phosphosite.
Gene Ontology Analysis
GeneOntology (GO) analysis of differentially expressed genes (72h vs 0h; Figure 4B) was performed using only genes that were up- or
down-regulated at both the mRNA and protein levels. To identify such genes, we integrated the proteomics and transcriptomics
data using a previously published strategy (Yang et al., 2014) to group genes into eight classes based on the following criteria:
(I) up-regulated at both the mRNA and protein levels, (II) up-regulated at the mRNA level but unchanged at the protein level, (III)
up-regulated at the mRNA level but down-regulated at the protein level, (IV) unchanged at the mRNA level but down-regulated at
the protein level, (V) down-regulated at both the mRNA and protein levels, (VI) down-regulated at the mRNA level but unchanged
at the protein level, (VII) down-regulated at the mRNA level but up-regulated at the protein level, and (VII) unchanged at the
mRNA level but up-regulated at the protein level. Class I (up-regulated) and class V (down-regulated) genes were analyzed for
enriched GO categories (Figure 4B) using GO annotations (Gene Ontology Consortium, 2015).
Kinase Activity Inference
To infer kinases active during ESC to EpiLC transition, we used CLUE (Yang et al., 2015), a fuzzy c-means clustering algorithm,
to partition all phosphosites into 12 optimal clusters based on their temporal profiles (Figures S5A and S5B), and identified, for
each cluster, kinases whose known substrates are enriched within that cluster. Known kinase-substrate relationships
annotated in the PhosphoSitePlus database (Hornbeck et al., 2012) were used as a reference, and Fisher’s exact test was
used to assess statistical significance of over-representation. Four out of the 12 clusters were found to be enriched for sub-
strates with known kinases ERK/S6K/RSK, mTOR, p38a, and AKT (Figures 3A and 3B). An independent kinase perturbation
analysis (Figure S5C) was performed using KinasePA (Yang et al., 2016b) to infer kinases active/regulated at various time-points
during ESC to EpiLC induction, based on known kinase-substrate relationships annotated in PhosphoSitePlus database (Horn-
beck et al., 2012).
Pathway Enrichment Analysis
Pathway enrichment analysis (Figure 3C) was performed using the list of genes that encode for proteins containing the phosphosites
from each of the inferred cluster. Pathway enrichment within a set of genes was evaluated by comparing that set of genes against
genes within known pathways, as annotated in the Reactome database (https://reactome.org). Fisher’s exact test was used to
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Substrate Prediction and Motif Analysis
Substrate prediction for ERK, mTOR, AKT, RSK/S6K and p38a was performed using an extendedmulticlass prediction version of the
positive-unlabeled ensemble learning (Yang et al., 2016a). Briefly, the ensemble learning algorithm obtains the positive training in-
stances by extracting known kinase-substrates fromPhosphoSitePlus database and combines themwith negative training instances
obtained by randomly sampling from the rest of all identified phosphorylation sites using a positive-unlabeled learning technique.
Throughout the training and prediction steps, the ensemblemodel integrates both the dynamic features extracted from time-resolved
phosphoproteomics temporal profiles and the kinase recognition motif compiled from known substrates of each kinase and subse-
quently performs a multiclass classification to predict novel substrates for each kinase. Prediction results from the model were
visualized as three-dimensional scatter plots with rainbow gradient colors from red to purple indicating most to least probable sub-
strates of each kinase (Figure S5D, inset). Prediction results were also clustered to show their proximity to other predicted substrates
of the same or a different kinase (Figure S5D). Consensus sequence motifs enriched within predicted substrates (Figure 3J) were
identified using IceLogo (Colaert et al., 2009), using precompiled mouse Swiss-Prot sequence composition as the reference set.
QUANTIFICATION AND STATISTICAL ANALYSIS
See Methods Details for details of quantification and statistical analysis.
DATA AND SOFTWARE AVAILABILITY
Mass spectrometry data generated for this study have been deposited to the ProteomeXchangeConsortium (http://proteomecentral.
proteomexchange.org/cgi/GetDataset), via the PRIDE (Deutsch et al., 2017) partner repository under PRIDE: PXD010621. RNA-Seq
and ChIP-Seq data generated for this study have been deposited in the GEO repository under the accession number GEO:
GSE117896. The processed data can be explored at http://www.stemcellatlas.org.Cell Systems 8, 427–445.e1–e10, May 22, 2019 e10
